
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Systems biology successes and areas for opportunity in prostate cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="1525463C8AF3276305463C001888A0B4.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="sfesd">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Endocrine-Related Cancer">
<meta name="citation_title" content="Systems biology successes and areas for opportunity in prostate cancer">
<meta name="citation_author" content="Michael V Orman">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA">
<meta name="citation_author" content="Laura S Graham">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, Department of Medical Oncology, Aurora, Colorado, USA">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA">
<meta name="citation_author" content="Scott D Cramer">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA">
<meta name="citation_author" content="James C Costello">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA">
<meta name="citation_author_institution" content="University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="32">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="e250067">
<meta name="citation_doi" content="10.1530/ERC-25-0067">
<meta name="citation_pmid" content="40840524">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/pdf/ERC-25-0067.pdf">
<meta name="description" content="Systems biology approaches have been applied to prostate cancer to model how individual cellular and molecular components interact to influence cancer development, progression, and treatment responses. The integration of multi-omic experimental data ...">
<meta name="og:title" content="Systems biology successes and areas for opportunity in prostate cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Systems biology approaches have been applied to prostate cancer to model how individual cellular and molecular components interact to influence cancer development, progression, and treatment responses. The integration of multi-omic experimental data ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12372069">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1530/ERC-25-0067"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ERC-25-0067.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12372069%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12372069/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12372069/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-sfesd.png" alt="Society for Endocrinology Open Access logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Society for Endocrinology Open Access" title="Link to Society for Endocrinology Open Access" shape="default" href="https://doi.org/10.1530/ERC-25-0067" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Endocr Relat Cancer</button></div>. 2025 Aug 20;32(8):e250067. doi: <a href="https://doi.org/10.1530/ERC-25-0067" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1530/ERC-25-0067</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Endocr%20Relat%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocr%20Relat%20Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Endocr%20Relat%20Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Endocr%20Relat%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Systems biology successes and areas for opportunity in prostate cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Orman%20MV%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Michael V Orman</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Michael V Orman</span></h3>
<div class="p">
<sup><sup>1</sup></sup>University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Orman%20MV%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael V Orman</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graham%20LS%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Laura S Graham</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Laura S Graham</span></h3>
<div class="p">
<sup><sup>2</sup></sup>University of Colorado Anschutz Medical Campus, Department of Medical Oncology, Aurora, Colorado, USA</div>
<div class="p">
<sup><sup>3</sup></sup>University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graham%20LS%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura S Graham</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cramer%20SD%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Scott D Cramer</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Scott D Cramer</span></h3>
<div class="p">
<sup><sup>1</sup></sup>University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA</div>
<div class="p">
<sup><sup>3</sup></sup>University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cramer%20SD%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott D Cramer</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Costello%20JC%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">James C Costello</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">James C Costello</span></h3>
<div class="p">
<sup><sup>1</sup></sup>University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA</div>
<div class="p">
<sup><sup>3</sup></sup>University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Costello%20JC%22%5BAuthor%5D" class="usa-link"><span class="name western">James C Costello</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup><sup>1</sup></sup>University of Colorado Anschutz Medical Campus, Department of Pharmacology, Aurora, Colorado, USA</div>
<div id="aff2">
<sup><sup>2</sup></sup>University of Colorado Anschutz Medical Campus, Department of Medical Oncology, Aurora, Colorado, USA</div>
<div id="aff3">
<sup><sup>3</sup></sup>University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center, Aurora, Colorado, USA</div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">Correspondence should be addressed to S D Cramer: <span>scott.cramer@cuanschutz.edu</span> or to J C Costello: <span>james.costello@cuanschutz.edu</span></p>
</div>
<div class="fn" id="fn1"><p>This paper forms part of the themed collection Systems Biology Approaches in Hormone Dependent Cancer Research. The Guest Editors were Moray Campbell and Robert Clarke.</p></div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 4; Revised 2025 Jul 3; Accepted 2025 Aug 1; Prepublished 2025 Aug 4; Issue date 2025 Aug 1.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© the author(s)</div>
<p><img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/12372069/bc114850879e/88x31.jpg" loading="lazy" alt="Inline graphic">This work is licensed under a <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution 4.0 International License.</a></p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12372069  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40840524/" class="usa-link">40840524</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Systems biology approaches have been applied to prostate cancer to model how individual cellular and molecular components interact to influence cancer development, progression, and treatment responses. The integration of multi-omic experimental data with computational models has provided insights into the molecular characteristics of prostate cancer and emerging treatment strategies that have the potential to improve patient outcomes. Here, we highlight recent advancements that have emerged from systems modeling in prostate cancer. These include descriptions of the molecular landscape of prostate cancer and how genomic alterations inform computational models of disease progression, how evolutionary processes give rise to mechanisms of therapeutic resistance, and the development of innovative treatment strategies such as adaptive therapy. We also highlight current challenges in prostate cancer that can be addressed through systems biology approaches. These include tumor heterogeneity, poor immunotherapy response, a paucity of experimental model systems, and the ongoing translation of computational models for clinical decision making. Leveraging systems biology approaches has the potential to lead to a better understanding of the disease and better patient outcomes in the treatment of prostate cancer.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> systems biology, prostate cancer, adaptive therapy, molecular landscape, tumor evolution</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Cancer cells and tumors are part of, and function within, systems, whether that is at the molecular level of signaling networks, within the local microenvironment of the organ where the cancer arose, or more broadly within the individual person. Cancer systems biology broadly aims to study how individual elements or components come together to function as a system to drive cancer development, progression, metastasis, and response to treatment (<a href="#bib1" class="usa-link" aria-describedby="bib1">1</a>, <a href="#bib2" class="usa-link" aria-describedby="bib2">2</a>, <a href="#bib3" class="usa-link" aria-describedby="bib3">3</a>). The components of the system can be molecules, which together give rise to signaling networks. The components can also be individual cells and cell types that can combine to drive cancer phenotypes in the tumor microenvironment. These systems can be perturbed in many ways, whether that is from somatic alterations or from pharmacological agents. The properties and phenotypes that emerge from these systems are what cancer systems biology aims to model (<a href="#bib4" class="usa-link" aria-describedby="bib4">4</a>), and in order to study these phenomena, we must have methods to measure the components of the system.</p>
<p>The rise of multi-omic data modalities and many sophisticated offshoots have given us the means to measure molecular components of tumors at the bulk and single-cell level. In addition, technological advances in quantification at the single-cell level have given us new methods to measure the cellular composition of tumors (<a href="#bib5" class="usa-link" aria-describedby="bib5">5</a>). The integration of these two approaches has more recently given us the ability to combine cell types with the molecular features in a spatially resolved manner within the tumor microenvironment (<a href="#bib6" class="usa-link" aria-describedby="bib6">6</a>). Prostate cancer has been at the forefront of systems biology modeling with successful basic research and early-stage clinical applications (<a href="#bib7" class="usa-link" aria-describedby="bib7">7</a>, <a href="#bib8" class="usa-link" aria-describedby="bib8">8</a>, <a href="#bib9" class="usa-link" aria-describedby="bib9">9</a>, <a href="#bib10" class="usa-link" aria-describedby="bib10">10</a>, <a href="#bib11" class="usa-link" aria-describedby="bib11">11</a>, <a href="#bib12" class="usa-link" aria-describedby="bib12">12</a>, <a href="#bib13" class="usa-link" aria-describedby="bib13">13</a>, <a href="#bib14" class="usa-link" aria-describedby="bib14">14</a>); however, prostate cancer has not had the same success at characterizing molecular mechanisms of tumor development and novel therapeutic targets as other cancers. Here, we will highlight the overall successes in cancer systems biology in the context of prostate cancer and also discuss where opportunities exist for systems biology approaches to continue to advance research and clinical translation in prostate cancer.</p>
<p>There are many features of prostate cancer that make it an ideal cancer type to apply systems modeling approaches. First, because it is the most common cancer in men in the United States and the second most common cancer in men worldwide (<a href="#bib15" class="usa-link" aria-describedby="bib15">15</a>), there are a large number of prostate cancer samples collected across many diverse clinical settings. As a result, prostate cancer is one of the most commonly sampled tumor types for multi-omics data modalities, providing researchers with a large number of molecular measurements (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib17" class="usa-link" aria-describedby="bib17">17</a>, <a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>, <a href="#bib19" class="usa-link" aria-describedby="bib19">19</a>, <a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>, <a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>, <a href="#bib22" class="usa-link" aria-describedby="bib22">22</a>, <a href="#bib23" class="usa-link" aria-describedby="bib23">23</a>, <a href="#bib24" class="usa-link" aria-describedby="bib24">24</a>, <a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>, <a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>). Second, we have strong evidence that molecular features of prostate cancer can be used to predict treatment outcomes and disease progression in multiple settings. There are commercially available molecular diagnostics for these purposes, such as Decipher (<a href="#bib27" class="usa-link" aria-describedby="bib27">27</a>), Oncotype DX (<a href="#bib28" class="usa-link" aria-describedby="bib28">28</a>), and Prolaris (<a href="#bib29" class="usa-link" aria-describedby="bib29">29</a>). Knowing that the molecular data of prostate cancer contain positive predictive information about patient outcomes supports further model development to understand the mechanisms of disease development and treatment response. Third, after establishing baseline levels, PSA can be easily measured using a blood draw and is a strong indicator of disease progression or regression, especially in the early course of the disease. Accordingly, PSA can be used as a proxy for tumor response to treatment and is a unique biomarker to prostate cancer. Fourth, and for almost all prostate cancers, we know the main causal driver of disease development and treatment resistance. The androgen receptor and androgen signaling are critical in almost all aspects of prostate cancer and allow us to focus model development on the most relevant molecular elements to the disease.</p>
<p>Because of these modeling advantages in prostate cancer, we have seen several important advancements in basic science and emerging treatment strategies. We highlight three areas where systems modeling and data integration have led to novel insights and strategies in studying and treating prostate cancer. These include large multi-omic data generation and integration efforts to characterize the molecular landscape of prostate cancer, the modeling of tumor evolution to gain insights into tumor dynamics that drive prostate cancer development, and how adaptive therapy anchored on PSA levels has led to better outcomes in the metastatic castration resistant prostate cancer (mCRPC) setting (<a href="#fig1" class="usa-link">Fig. 1</a>). While these results are exciting and demonstrate the promise of systems biology approaches in prostate cancer, there remain a number of challenges. Accordingly, we conclude by discussing these challenges, including tumor heterogeneity, the immune microenvironment, tumor suppressors as drivers of prostate cancer, and experimental model systems. These challenges highlight the opportunities for future growth and development of systems modeling in prostate cancer.</p>
<figure class="fig xbox font-sm" id="fig1"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372069_ERC-25-0067fig1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/12372069/ef2064722533/ERC-25-0067fig1.jpg" loading="lazy" height="463" width="793" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Systems biology framework for conducting prostate cancer research. Experimental models and patient-derived samples provide information in the form of multi-omics datasets, which are analyzed by a wide range of computational methods. Predictions generated by computational modeling are formed into testable experimental hypotheses that can be evaluated in these same model systems.</p></figcaption></figure></section><section id="sec91"><h2 class="pmc_sec_title">The molecular landscape of prostate cancer is defined by loss of tumor suppressor genes and chromosomal instability</h2>
<p>The molecular landscape of primary prostate cancer has been well-characterized through numerous tumor profiling studies published over the past two decades (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib17" class="usa-link" aria-describedby="bib17">17</a>, <a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>, <a href="#bib19" class="usa-link" aria-describedby="bib19">19</a>, <a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>, <a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>, <a href="#bib22" class="usa-link" aria-describedby="bib22">22</a>, <a href="#bib23" class="usa-link" aria-describedby="bib23">23</a>, <a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>, <a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>, <a href="#bib30" class="usa-link" aria-describedby="bib30">30</a>). These studies have found that the prostate cancer genome is characterized primarily by structural variation in the form of gene fusion events and copy number alterations (CNAs). In primary tumors, rearrangements involving ETS-family transcription factors and androgen-regulated genomic elements are found in a large percentage of cases and contribute to oncogenic overexpression of ETS-family fusion transcripts (<a href="#bib30" class="usa-link" aria-describedby="bib30">30</a>). The most common example is the fusion of the androgen-responsive <em>TMPRSS2</em> gene promoter to the 5′ end of the <em>ERG</em> gene (<a href="#bib30" class="usa-link" aria-describedby="bib30">30</a>). The <em>TMPRSS2</em> and <em>ERG</em> fusion occurs through translocation and deletion events and the prevalence of this alteration varies between 16 and 50% depending on patient ancestry (<a href="#bib31" class="usa-link" aria-describedby="bib31">31</a>). Additional ETS-family transcription factors that undergo fusion events include <em>ETV1, ETV4,</em> and <em>FLI1</em> (<a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>). CNAs are abundant in primary prostate cancer and have prognostic value when predicting biochemical recurrence and metastasis-free survival (<a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>, <a href="#bib32" class="usa-link" aria-describedby="bib32">32</a>). Combined analysis of over 900 primary tumors across five independent profiling cohorts was performed using a harmonized prostate cancer data resource (<a href="#bib24" class="usa-link" aria-describedby="bib24">24</a>). This analysis confirmed several tumor suppressor genes playing a role in disease progression that are found in regions of heavy genomic loss spanning 5q11-5q23 (<em>CHD1</em>), 6q12-6q22 (<em>MAP3K7</em>), 8p11-8p23 (<em>NKX3-1</em>), 10q22-10q26 (<em>PTEN</em>), and 13q12-13q24 (<em>RB1</em>) (<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>). As shown in <a href="#fig2" class="usa-link">Fig. 2</a>, further stratification of primary tumors based on the Gleason scoring system show that these regions of copy number loss are enriched throughout the primary prostate cancer disease spectrum. <em>NKX3-1</em> is the most commonly lost tumor suppressor gene in primary tumors, with its deletion found in about half of patients, and is among the first alterations to occur in prostate cancer development (<a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>, <a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>). Loss of <em>NKX3-1</em> is associated with PIN in human samples and also drives PIN development in the mouse prostate (<a href="#bib35" class="usa-link" aria-describedby="bib35">35</a>). <em>MAP3K7</em> and <em>RB1</em> are also some of the most commonly lost tumor suppressor genes in primary tumors at roughly 30 and 34%, respectively (<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>). Loss of <em>MAP3K7</em> expression is associated with biochemical recurrence and aggressive Gleason scores, and drives prostate tumorigenesis in mice (<a href="#bib36" class="usa-link" aria-describedby="bib36">36</a>, <a href="#bib37" class="usa-link" aria-describedby="bib37">37</a>). Interestingly, <em>RB1</em> loss has been identified as an alteration occurring early in prostate cancer development that drives clinical aggression through subclonal diversification (<a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>). Deletion mapping studies have found loss of <em>PTEN</em> in 26% of prostate tumors and functional analysis in murine models has shown that homozygous <em>PTEN</em> loss is sufficient to drive disease progression from early stages of prostate cancer formation to metastatic disease (<a href="#bib38" class="usa-link" aria-describedby="bib38">38</a>, <a href="#bib39" class="usa-link" aria-describedby="bib39">39</a>). In addition, loss of the chromatin-remodeling protein <em>CHD1</em>, in about 20% of tumors, reprograms the <em>AR</em> cistrome into an oncogenic state and contributes to tumor progression (<a href="#bib40" class="usa-link" aria-describedby="bib40">40</a>). Amplifications are less common than gene deletion in primary tumors. Nonetheless, the most amplified regions observed in primary tumors span chromosomes 3q22-3q26, 8q11-8q24, and chromosome 7 (<a href="#fig2" class="usa-link">Fig. 2</a>) (<a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>). These regions harbor known oncogenes driving prostate cancer, including <em>MYC, NCOA2, PIK3CA,</em> and <em>ETV1</em>, and also implicate genes with recently-discovered oncogenic functions such as <em>PLXNA1</em> (<a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>, <a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>).</p>
<figure class="fig xbox font-sm" id="fig2"><h3 class="obj_head">Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372069_ERC-25-0067fig2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/12372069/98e117c76435/ERC-25-0067fig2.jpg" loading="lazy" height="330" width="687" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The CNA landscape of primary and metastatic castration-resistant prostate cancer (mCRPC). Analysis of CNA rates in primary tumors is stratified according to the Gleason scoring system. Copy number gains are shown in orange and copy number losses are shown in blue.</p></figcaption></figure><p>In addition to extensive structural variation, the genomic instability of prostate cancer gives rise to low-frequency mutations that impact prostate cancer progression. Initial efforts to profile mutations in 112 treatment-naive primary prostate samples with matched normal tissue identified 12 significant mutations across several cancer genes, including <em>TP53, PTEN, PIK3CA,</em> and <em>CDKN1B</em> (<a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>). Novel mutations were also identified in <em>FOXA1, MED12,</em> and <em>SPOP</em> (<a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>). <em>SPOP</em> was the most highly mutated gene found in 13% of samples and follow-up work has now solidified <em>SPOP</em> loss-of-function mutations as robust drivers of prostate cancer (<a href="#bib20" class="usa-link" aria-describedby="bib20">20</a>, <a href="#bib41" class="usa-link" aria-describedby="bib41">41</a>, <a href="#bib42" class="usa-link" aria-describedby="bib42">42</a>). Mutation profiling by TCGA has confirmed the prevalence of <em>SPOP</em> and <em>FOXA1</em> mutations and discovered <em>IDH1</em> as a recurrently mutated gene that defines primary tumors (<a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>). Larger-scale genomic characterization pooling over 1,000 primary and metastatic prostate cancer samples found 97 significantly mutated genes, with groups of these genes functioning in WNT, spliceosome, proteasomal degradation, and epigenetic signaling pathways (<a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>).</p>
<p>The molecular landscape of mCRPC has also been well-defined in recent years. Profiling studies show that mCRPC is characterized by a high alteration and mutation burden, and increased alteration frequency to potent disease drivers including <em>AR</em> and the tumor suppressor genes <em>TP53, RB1,</em> and <em>PTEN</em> (<a href="#fig2" class="usa-link">Fig. 2</a>) (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib19" class="usa-link" aria-describedby="bib19">19</a>, <a href="#bib25" class="usa-link" aria-describedby="bib25">25</a>, <a href="#bib26" class="usa-link" aria-describedby="bib26">26</a>, <a href="#bib43" class="usa-link" aria-describedby="bib43">43</a>). <em>AR</em> amplification is observed in roughly half of mCRPC cases and is mutated in about 10% of cases (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib43" class="usa-link" aria-describedby="bib43">43</a>). <em>TP53</em> is the most highly mutated gene in mCRPC observed in about 30% of cases with almost all of these mutations predicted as oncogenic (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib43" class="usa-link" aria-describedby="bib43">43</a>). <em>PTEN</em> and <em>RB1</em> are also significantly mutated in mCRPC; however, these genes are largely enriched with copy number loss resulting in deletion frequencies of about 30 and 15%, respectively (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib43" class="usa-link" aria-describedby="bib43">43</a>). Common mCRPC alterations have also been grouped at the pathway level to identify dysregulated signaling pathways contributing to aggressiveness. In particular, alterations in genes regulating AR, PI3K/Akt, WNT, DNA-repair, cell cycle, and epigenetic signaling pathways are commonly observed in the mCRPC setting (<a href="#bib16" class="usa-link" aria-describedby="bib16">16</a>, <a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>, <a href="#bib19" class="usa-link" aria-describedby="bib19">19</a>). Several of the genomic alterations that are enriched in mCRPC have been used to define the neuroendocrine prostate cancer (NEPC) subtype. NEPC is largely found in metastases late in disease development as an adaptive response to inhibiting the AR signaling axis with ARSI therapies (<a href="#bib44" class="usa-link" aria-describedby="bib44">44</a>). Characterization of NEPC biopsies has found loss of AR expression and its downstream targets combined with the loss of tumor suppressors including TP53, RB1, and PTEN (<a href="#bib45" class="usa-link" aria-describedby="bib45">45</a>). Another defining feature of NEPC is the induced expression of neuroendocrine markers such as synaptophysin (SYP), chromogranin A (CHGA), CD56, neuron-specific enolase (NSE), and bombesin (BRS3) (<a href="#bib45" class="usa-link" aria-describedby="bib45">45</a>). Rigorous phenotypic characterization of mCRPC tumors and PDX models has further reinforced the importance of AR and neuroendocrine features in classifying advanced prostate cancer. This work defined five subclasses of mCRPC: uniformly AR-expressing tumors with no neuroendocrine features (ARPC), tumors with weak or diffuse AR expression and no neuroendocrine features (AR-low prostate cancer, or ARLPC), tumors expressing both AR and neuroendocrine markers (amphicrine prostate cancer or AMPC), AR-negative tumors with neuroendocrine features (small cell/neuroendocrine prostate cancer, or SCNPC), and tumors that exhibit neither AR expression nor small-cell neuroendocrine features (double-negative prostate cancer or DNPC) (<a href="#bib46" class="usa-link" aria-describedby="bib46">46</a>).</p>
<p>The alterations defining prostate cancer do not occur in isolation but rather co-occur with one another throughout the disease spectrum. A number of research groups have addressed the topic of multigenic molecular subtypes to understand how combinations of prostate cancer alterations may cooperate to drive aggressiveness. Dual loss of <em>NKX3-1</em> and <em>PTEN</em> is a well-characterized example of coordinating alterations in prostate cancer. In a tissue recombination system with serial transplantation, mice with heterozygous loss of <em>NKX3-1</em> and <em>PTEN</em> developed high-grade PIN with invasive adenocarcinoma in 84% of cases and lymph node metastasis in 25% of cases (<a href="#bib47" class="usa-link" aria-describedby="bib47">47</a>). Mice with only <em>NKX3-1</em> loss showed neither of these aggressive phenotypes and mice with only <em>PTEN</em> loss showed invasive adenocarcinoma in 54% of cases and no lymph node metastasis, indicating heterozygous loss of <em>NKX3-1</em> or <em>PTEN</em> alone is insufficient to drive metastasis (<a href="#bib47" class="usa-link" aria-describedby="bib47">47</a>). Mechanistically, <em>PTEN</em> and <em>NKX3-1</em> interact in the nucleus where <em>PTEN</em> functions as an <em>NKX3-1</em> phosphatase to protect <em>NKX3-1</em> from degradation (<a href="#bib48" class="usa-link" aria-describedby="bib48">48</a>). <em>PTEN</em> loss has also been shown to drive aggressive prostate cancer in combination with <em>RB1</em> and <em>TP53</em> loss (<a href="#bib49" class="usa-link" aria-describedby="bib49">49</a>). In conditional knockout models, <em>Rb1</em> loss is sufficient to drive metastasis and lineage plasticity following tumor formation driven by <em>Pten</em> loss. Additional <em>Trp53</em> loss was modeled in these double-knockout mice, resulting in resistance to antiandrogen therapy (<a href="#bib49" class="usa-link" aria-describedby="bib49">49</a>). <em>TMPRSS2–ERG</em> fusion and <em>PTEN</em> loss is another example of coordinating interactions in prostate cancer. Aberrant <em>ERG</em> overexpression in the mouse prostate did not have a significant phenotype, while heterozygous loss of <em>PTEN</em> results in high-grade PIN by 8 months of age (<a href="#bib50" class="usa-link" aria-describedby="bib50">50</a>, <a href="#bib51" class="usa-link" aria-describedby="bib51">51</a>). However, when mice were engineered to have prostatic <em>ERG</em> overexpression on a heterozygous <em>Pten</em> background, this resulted in multifocal prostatic adenocarcinoma by 6 months of age (<a href="#bib51" class="usa-link" aria-describedby="bib51">51</a>). Further characterization showed that ERG promotes transcriptional upregulation of <em>CXCR4</em> and <em>ADAMTS1</em>, both of which regulate cell migration (<a href="#bib51" class="usa-link" aria-describedby="bib51">51</a>). Another example is the co-loss of <em>MAP3K7</em> and <em>CHD1</em>, two tumor suppressor genes, which coordinate to drive disease aggressiveness. In a developmental model based on tissue recombination, co-suppression of <em>CHD1</em> and <em>MAP3K7</em> drove the formation of high-grade PIN and intraductal carcinoma <em>in vivo</em> (<a href="#bib52" class="usa-link" aria-describedby="bib52">52</a>). These pathological features coincided with sporadic clusters of <em>SYP</em> expression, indicating neuroendocrine differentiation (<a href="#bib52" class="usa-link" aria-describedby="bib52">52</a>). Mechanistic analysis of this subtype has shown that the co-suppression of <em>CHD1</em> and <em>MAP3K7</em> cooperatively boosts AR signaling by increasing AR nuclear translocation and chromatin binding (<a href="#bib37" class="usa-link" aria-describedby="bib37">37</a>).</p></section><section id="sec1-2"><h2 class="pmc_sec_title">The molecular landscape of prostate cancer in systems biology modeling</h2>
<p>Defining the molecular landscape of prostate cancer is a critical first step in understanding how these alterations contribute to disease development, progression, and therapy response. Systems biology approaches leverage this information to model how alterations can affect molecular pathways and processes driving cancer phenotypes. Montagud <em>et al.</em> leveraged a Boolean model and integrated 498 prostate cancer samples sourced from TCGA along with cell line information sourced from the Genomics of Drug Sensitivity in Cancer (GDSC) database (<a href="#bib53" class="usa-link" aria-describedby="bib53">53</a>). A cancer signaling Boolean network was adapted from Fumiã <em>et al.</em> to further capture the known regulatory relationships between common prostate cancer alterations (<a href="#bib54" class="usa-link" aria-describedby="bib54">54</a>). <em>NKX3-1</em> deletion was modeled by deleting the node required for the activation of TMPRSS2:ERG by AR. <em>SPOP</em> mutations were modeled by removing the node that triggers apoptosis in the presence of cell death factors. Invasion was encoded by the activation of a combination of <em>CHD2, SMAD,</em> and <em>EZH2</em>. Progression to bone metastasis was activated by a set of invasion and migration modules combined with the activation of ERG, FLI1, ETV1, or ETV4 fusions (<a href="#bib10" class="usa-link" aria-describedby="bib10">10</a>). The modified networks were used as patient and cell line-specific models to investigate mechanisms of tumorigenesis and tumor growth. Patient-specific model simulations validated increased proliferation and decreased apoptosis in models trained on the high-grade samples compared to the low-grade ones. This approach was applied to LNCaP cells to generate a cell line-specific model that identified druggable targets, including HSP90 and PI3K (<a href="#bib10" class="usa-link" aria-describedby="bib10">10</a>).</p>
<p>Using a different modeling approach, Kuipers <em>et al.</em> trained a Bayesian network using pan-cancer mutational profiles spanning 22 different cancer types and 201 non-silent mutations (<a href="#bib55" class="usa-link" aria-describedby="bib55">55</a>). This dataset contained 498 prostate adenocarcinoma samples harboring mutations in canonical prostate cancer genes, including <em>TP53, RB1, PTEN, BRCA PIK3CA,</em> and <em>SPOP</em>. Across all cancer types, various mutational dependencies in genes such as <em>TP53</em> and <em>MLL2</em> that encompassed multiple cancer types were revealed. Dependencies that were specifically associated with prostate cancer included co-occurring mutations between <em>KEAP1</em> and <em>JUB, SPOP</em> and <em>EME2,</em> and <em>EME2</em> and <em>ARIDA1</em> (<a href="#bib55" class="usa-link" aria-describedby="bib55">55</a>). Features extracted from this modeling approach were further used to define subgroups and provide an alternate stratification scheme for predicting prostate cancer prognosis based solely on mutational status (<a href="#bib55" class="usa-link" aria-describedby="bib55">55</a>). In another example of Bayesian modeling, Blatti <em>et al.</em> sourced transcriptional data from mCRPC patients classified as either responders or non-responders following abiraterone and prednisone dual-therapy (<a href="#bib56" class="usa-link" aria-describedby="bib56">56</a>). These transcriptional data were used to train a sparse Bayesian network followed by differential network analysis to identify rewiring of the model that was associated with castration resistance. The approach, named TraRe, identified several well-known transcription factors regulating key network modules, the most notable being an immune response module driven by <em>GATA1, CEBPE, KLF1,</em> and <em>MYB</em> transcriptional activity. TraRe predictions were tested using abiraterone-sensitive prostate cancer cell lines to confirm the function of <em>ELK3, MXD1,</em> and <em>MYB</em> in promoting castration-resistant growth (<a href="#bib56" class="usa-link" aria-describedby="bib56">56</a>).</p>
<p>Overall, the molecular landscape of prostate cancer provides the features needed to develop and test systems biology models, including tumor initiation, growth, and the development of castration resistance. The accuracy of the models depends on a robust characterization of the molecular features associated with aggressive prostate cancer. These computational models have generated novel hypotheses that can then be tested using experimental models to establish causal variables in the etiology of prostate cancer.</p></section><section id="sec1-3"><h2 class="pmc_sec_title">The evolution of prostate cancer follows several trajectories</h2>
<p>Prostate cancer progression can be modeled as an evolutionary process by which the accumulation of genomic alterations during the lifetime of the tumor promotes development, progression, and metastasis. Work in this area has leveraged whole genome sequencing (WGS) data to generate CNA and single nucleotide variant (SNV) profiles, which can be used to reconstruct the temporal sequence of alterations occurring over tumor progression. Analysis of CNA clonality has shown <em>NKX3-1</em> deletion, <em>RB1</em> deletion, <em>FOXP1</em> deletion, and <em>ERG</em> rearrangement are the earliest forms of structural variation occurring in prostate cancer evolution (<a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>, <a href="#bib57" class="usa-link" aria-describedby="bib57">57</a>). Occurring alongside these structural variants, analysis of SNV clonality identified <em>ATM, FOXA1, SPOP</em> and <em>TP53</em> mutations as early evolutionary events (<a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>, <a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>). These data have been used to propose evolutionary trajectories of prostate cancer tumors. Baca <em>et al.</em> proposed a consensus path of progression that starts with deletions in <em>NKX3-1</em>, <em>FOXP1</em>, and <em>TMPRSS2-ERG</em> (<a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>). From there, alterations in <em>TP53</em> and <em>CDKN1B</em> promote tumor growth and are eventually followed by loss of <em>PTEN</em> to drive prostate cancer aggressiveness (<a href="#bib21" class="usa-link" aria-describedby="bib21">21</a>). Espiritu <em>et al.</em> proposed a different evolutionary trajectory defined by early loss of <em>NKX3-1</em> and <em>RB1</em> and SNVs in <em>FOXA1</em> and <em>ATM</em> (<a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>). These initiating alterations are then followed by driver SNVs in <em>SPOP</em> and <em>TP53</em>; afterward, subclonal driver amplifications accumulate in genes including <em>MTOR</em>, <em>TCS1, TCS2, MAF, BAD, BID</em>, and <em>BAK1</em> (<a href="#bib34" class="usa-link" aria-describedby="bib34">34</a>). Additional work assessing CNA clonality described distinct phylogenies of alterations occurring in <em>ETS</em> transcription factor fusion positive (<em>ETS+</em>) and <em>ETS</em> fusion negative (<em>ETS</em>−) prostate tumors. <em>ETS</em>+ tumors were defined by an early <em>TMPRSS2</em>–<em>ERG</em> fusion, followed by early gains of chr8q, and then subsequent homozygous deletion to chr5 (<em>PPAP2A</em>, <em>PDE4D</em>, <em>MAP3K1</em> and <em>IL6ST</em>) and chr10 (<em>PTEN</em>) (<a href="#bib58" class="usa-link" aria-describedby="bib58">58</a>). Early homozygous deletions at chr5 (<em>CHD1</em> and <em>RGMB</em>) and chr13 (<em>RB1, BRCA2,</em> and <em>FOXO1</em>) defined <em>ETS−</em> tumors, which were then followed by deletions to chr2, gains to chr3, and finally gain across the entirety of chr7 (<a href="#bib58" class="usa-link" aria-describedby="bib58">58</a>). This work also analyzed SNVs and found that 84 were clonal and 22 were subclonal, with frequent <em>SPOP</em> mutations that were exclusive to <em>ETS+</em> tumors (<a href="#bib58" class="usa-link" aria-describedby="bib58">58</a>). More recent work using WGS proposed a novel evolutionary model, referred to as evotypes, of primary prostate cancer (<a href="#bib59" class="usa-link" aria-describedby="bib59">59</a>). This analysis defined two evolutionary subclasses of tumors, named the canonical evotype and the alternative evotype. Canonical evotype tumors were associated with frequent early <em>ETS</em> fusions and less frequent early deletions to loci harboring <em>PTEN, TP53, RB1,</em> and <em>CDH1</em> (<a href="#bib59" class="usa-link" aria-describedby="bib59">59</a>). Alternative evotype tumors were defined by very early, low-frequency <em>SPOP</em> mutations and followed by abundant early-stage <em>MAP3K7, CHD1,</em> and <em>RB1</em> deletions (<a href="#bib59" class="usa-link" aria-describedby="bib59">59</a>). Consistent with previous work, <em>NKX3-1</em> deletion was found as an early alteration at high rates in both the canonical and alternative evotypes (<a href="#bib59" class="usa-link" aria-describedby="bib59">59</a>). Evolutionary models based on gene expression have also been developed to track tumor evolution within subtypes. This work showed that <em>TMPRSS2</em>–<em>ERG</em> fusions and <em>SPOP</em> mutations are clonal while <em>PTEN</em> and <em>CHD1</em> deletions have subclonal fractions (<a href="#bib60" class="usa-link" aria-describedby="bib60">60</a>). From this, two alteration trajectories have been proposed, including an <em>ERG</em> fusion to <em>PTEN</em> deletion path and a <em>SPOP</em> mutation to <em>CHD1</em> deletion path, with each of these trajectories displaying distinct clinicopathologic characteristics (<a href="#bib60" class="usa-link" aria-describedby="bib60">60</a>).</p>
<p>Given the abundance of CNA data available from multiple independent profiling studies in prostate cancer, we generated a CNA landscape stratified by Gleason grade to summarize the key alterations in early-stage disease and show their increasing prevalence over the course of tumor evolution (<a href="#fig2" class="usa-link">Fig. 2</a>). In concordance with findings from studies focusing on tumor evolution, our analysis of CNAs clearly identifies <em>NKX3-1, RB1, MAP3K7, CDKN1B, TP53,</em> and <em>ERG</em> copy number losses as strongly enriched CNAs observed in the earliest stages of prostate cancer (<a href="#fig2" class="usa-link">Fig. 2</a>). We also confirm copy number gains to chromosome 7 and chromosome 8q as early-stage alterations in prostate cancer development (<a href="#fig2" class="usa-link">Fig. 2</a>). Future efforts to model prostate cancer evolution will benefit from including these alterations as initiating or early-stage events when designing and evaluating systems biology models.</p></section><section id="sec1-4"><h2 class="pmc_sec_title">Adaptive therapy directly integrates computational modeling into treatment regimens</h2>
<p>Paradigms of clinical care of prostate cancer can be in conflict with how the disease develops and evolves in response to treatment. In the metastatic setting, treatment almost always starts with androgen deprivation therapy (ADT). Treatment is often effective at first, but the cancer eventually progresses past ADT into the metastatic castration-resistant setting. Attempts were made to treat prostate cancer in the metastatic (<a href="#bib61" class="usa-link" aria-describedby="bib61">61</a>) and non-metastatic setting (<a href="#bib62" class="usa-link" aria-describedby="bib62">62</a>, <a href="#bib63" class="usa-link" aria-describedby="bib63">63</a>) using intermittent ADT compared to continuous treatment (combinations of luteinizing hormone-releasing hormone (LHRH) analogs and antiandrogens). Intermittent ADT was hypothesized to potentially reduce selective evolutionary pressure toward treatment resistance while also allowing patients meaningful treatment breaks designed to improve the quality of life. The results showed little to no difference in clinical cancer outcomes using intermittent ADT. In these clinical trials, patients underwent an induction phase of ADT and then proceeded with a fixed schedule of intermittent or continuous ADT. While the trial design offered a new treatment schedule for patients, the same schedule was applied to all patients, which did not allow for adjusting the schedule or dosing based on an individual’s response to treatment.</p>
<p>Gatenby and colleagues approached treatment resistance from an ecological perspective and developed computational models of how prostate cancer tumor cells interact given environmental constraints and cellular interactions (<a href="#bib8" class="usa-link" aria-describedby="bib8">8</a>, <a href="#bib9" class="usa-link" aria-describedby="bib9">9</a>, <a href="#bib64" class="usa-link" aria-describedby="bib64">64</a>, <a href="#bib65" class="usa-link" aria-describedby="bib65">65</a>, <a href="#bib66" class="usa-link" aria-describedby="bib66">66</a>, <a href="#bib67" class="usa-link" aria-describedby="bib67">67</a>, <a href="#bib68" class="usa-link" aria-describedby="bib68">68</a>). The models derived from these principles showed that if certain dominant tumor cell populations were selectively removed through simulated drug treatment, then other populations that were suppressed by the dominant population were allowed to expand. Termed competitive release, these suppressed populations were both resistant to the treatment and more aggressive if allowed to expand. Thus, the treatment itself selects for tumor cells that drive treatment resistance and aggressiveness of disease, ultimately leading to death due to mCRPC.</p>
<p>The models by Gatenby and colleagues led to clinical trials of an alternative treatment approach where metastatic prostate cancer was treated with AR targeted therapy, but with early treatment breaks to allow for persistence of sensitive cells. In contrast to the fixed schedule with prior intermittent therapy trials, in the pilot study of men with mCRPC treated with ADT and the AR signaling inhibitor (ARSI) abiraterone, abiraterone was paused if PSA levels reached 50% of the baseline level and then restarted when PSA levels returned back or exceeded pretreatment baseline. ADT was maintained throughout. This approach, termed adaptive therapy, is customizable to every patient. A total of 16 men were in the adaptive therapy arm and 11 men in the standard of care, control arm. Men receiving adaptive therapy showed a radiographic progression-free survival of 30.4 months compared to 14.3 months and a median overall survival of 58.5 months compared to 31.3 months in the control arm (<a href="#bib67" class="usa-link" aria-describedby="bib67">67</a>, <a href="#bib69" class="usa-link" aria-describedby="bib69">69</a>). Both results were highly statistically significant and men receiving adaptive therapy received fewer treatments, resulting in an estimated $70,000 reduction in cost per patient per year (<a href="#bib70" class="usa-link" aria-describedby="bib70">70</a>). Another theoretical benefit of adaptive therapy is the opportunity for patients to have treatment holidays which may improve patient reported outcomes, including health-related quality of life, sexual functioning, and emotional and physical well-being. A phase 1b study in men with metastatic castration-sensitive prostate cancer (mCSPC) was performed by cycling a LHRH analog and an ARSI (i.e., abiraterone, enzalutamide, or apalutamide). Treatment was paused if PSA levels decreased by 75% after 12–16 weeks of therapy and restarted at the time of radiographic or PSA progression (<a href="#bib69" class="usa-link" aria-describedby="bib69">69</a>). This study demonstrated the feasibility of this approach; however, both trials are limited by their small sample size and lack of prospective randomization. Further validation is needed before this approach becomes more widely adopted.</p>
<p>The use of mathematical models was critical in the development of adaptive therapy (<a href="#bib65" class="usa-link" aria-describedby="bib65">65</a>, <a href="#bib71" class="usa-link" aria-describedby="bib71">71</a>, <a href="#bib72" class="usa-link" aria-describedby="bib72">72</a>, <a href="#bib73" class="usa-link" aria-describedby="bib73">73</a>). In prostate cancer, these models continue to evolve to include additional treatment regimens, such as docetaxel in the mCRPC setting (<a href="#bib68" class="usa-link" aria-describedby="bib68">68</a>, <a href="#bib74" class="usa-link" aria-describedby="bib74">74</a>). In addition, modeling approaches can consider the impact of spatial architecture on treatment response (<a href="#bib75" class="usa-link" aria-describedby="bib75">75</a>), along with how the treatment shapes the local tumor microenvironment (<a href="#bib76" class="usa-link" aria-describedby="bib76">76</a>, <a href="#bib77" class="usa-link" aria-describedby="bib77">77</a>). In addition, the adaptive therapy paradigm has been expanded to include not only treatment cycling, but also dose modulation in response to treatment. Dose modulation is responsive to tumor size with an increase in dose if there is a tumor size increase over 20% and a decrease in dose if there is a decrease by 20% (<a href="#bib8" class="usa-link" aria-describedby="bib8">8</a>, <a href="#bib65" class="usa-link" aria-describedby="bib65">65</a>, <a href="#bib78" class="usa-link" aria-describedby="bib78">78</a>). There is active research to expand this approach to other cancer types, including in melanoma (<a href="#bib79" class="usa-link" aria-describedby="bib79">79</a>, <a href="#bib80" class="usa-link" aria-describedby="bib80">80</a>, <a href="#bib81" class="usa-link" aria-describedby="bib81">81</a>), breast (<a href="#bib82" class="usa-link" aria-describedby="bib82">82</a>, <a href="#bib83" class="usa-link" aria-describedby="bib83">83</a>), colorectal (<a href="#bib84" class="usa-link" aria-describedby="bib84">84</a>), and ovarian cancers (<a href="#bib85" class="usa-link" aria-describedby="bib85">85</a>). Dose modulation may be challenging to apply to metastatic prostate cancer, which often has bone-predominant disease, where assessment of tumor volume is difficult. The adaptive therapy paradigm requires more research and clinical trials to evaluate its overall effectiveness, although the fact that the first clinical trials were performed in prostate cancer demonstrates that systems biology approaches can be effective in this cancer type.</p></section><section id="sec1-5"><h2 class="pmc_sec_title">Challenges that limit systems modeling in prostate cancer</h2>
<p>While the previous examples demonstrate that systems biology approaches and multi-omics have led to important basic research and clinical insights, there are some fundamental challenges that prostate cancer researchers face, including tumor heterogeneity, the lack of a strong immune contribution to the prostate cancer microenvironment for translation of immune checkpoint inhibitors, the observation that prostate cancer is driven by loss of tumor suppressors, and the lack of cell culture models that accurately represent the diversity of genomic alterations and primary tumor pathology.</p>
<p>Prostate tumor heterogeneity can take many forms, including, pathological, genetic, the tumor microenvironment, and the secretome. Heterogeneity can be between two tumors from different individuals (i.e., different genetic subtypes or pathological grades or patterning) or between different tumors within the same individual. Unlike many tumor types, it is not uncommon to find multiple, independent foci in an individual’s prostate (<a href="#bib86" class="usa-link" aria-describedby="bib86">86</a>). The Gleason scoring system identifies the two most dominant patterns that are observed by the scoring pathologist, regardless of how many patterns or foci of tumor are observed. The index tumor is generally considered the clinically actionable tumor with other tumors considered incidental (<a href="#bib86" class="usa-link" aria-describedby="bib86">86</a>). Boutros <em>et al.</em> examined CNAs, SNVs, and WGS data in index tumors of intermediate risk (Gleason 7) (<a href="#bib87" class="usa-link" aria-describedby="bib87">87</a>). The data demonstrated that foci can arise either from a common cell of origin or from independent clones (<a href="#bib87" class="usa-link" aria-describedby="bib87">87</a>). The foci derived from independent foci can represent distinct cancers that may require different therapeutic strategies. One tumor had nine independent foci sampled for WGS. Two Gleason 7 foci (including the index focus) had a <em>PIK3CA</em> mutation and loss of <em>TP53</em>. The <em>PIK3CA</em> mutation was predicted to make AKT inhibition an actionable therapeutic strategy. The other seven foci lacked this mutation. In contrast, four of the other foci had loss of <em>BRCA2</em> but retained <em>TP53</em>. The approach to therapy in a patient with such heterogeneous individual foci is a major challenge that will require longitudinal sampling and systems modeling. In mCRPC, intertumoral heterogeneity can be present between metastatic sites, with subclonal genetic diversity conferring the ability for treatment resistant clones to be selected (<a href="#bib88" class="usa-link" aria-describedby="bib88">88</a>). On top of these findings, treatment also contributes to subclone selection, adding additional complexity to the modeling of prostate cancer tumor heterogeneity (<a href="#bib89" class="usa-link" aria-describedby="bib89">89</a>).</p>
<p>Prostate cancer is characterized as a ‘cold’ tumor, meaning the tumor microenvironment in the prostate tends to be immunosuppressive and show little to no immune activation (<a href="#bib90" class="usa-link" aria-describedby="bib90">90</a>). While there have been positive associations made with immune cell populations, patient outcomes, and treatment response, the associations are in a minority of the population of prostate cancer patients. The predictive value of immune-related signatures is poor with only a small subset of patients (e.g., CDK12 mutations, mismatch repair deficient, and high microsatellite instability) benefiting from immune checkpoint inhibitors (<a href="#bib91" class="usa-link" aria-describedby="bib91">91</a>, <a href="#bib92" class="usa-link" aria-describedby="bib92">92</a>, <a href="#bib93" class="usa-link" aria-describedby="bib93">93</a>, <a href="#bib94" class="usa-link" aria-describedby="bib94">94</a>). The benefits of the immune system in contributing to disease progression in hot vs cold tumors was first described in colorectal cancer and showed a 2-year relapse rate of 10 vs 80%, respectively (<a href="#bib95" class="usa-link" aria-describedby="bib95">95</a>). Subsequent studies have validated these findings (<a href="#bib96" class="usa-link" aria-describedby="bib96">96</a>, <a href="#bib97" class="usa-link" aria-describedby="bib97">97</a>), with new ways to score tumors on their likelihood of response to immune checkpoint inhibitors based on immune cell infiltration into the tumor microenvironment (<a href="#bib98" class="usa-link" aria-describedby="bib98">98</a>). More recent work has shown efficacy of turning cold tumors into T-cell inflamed tumors, resulting in stronger and more durable response with immune checkpoint inhibitors (<a href="#bib99" class="usa-link" aria-describedby="bib99">99</a>, <a href="#bib100" class="usa-link" aria-describedby="bib100">100</a>, <a href="#bib101" class="usa-link" aria-describedby="bib101">101</a>). In prostate cancer, there are several mechanisms that drive an immunosuppressive microenvironment, including the function of regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells, interactions with stromal cells, and production of adenosine from prostatic acid phosphatase (<a href="#bib102" class="usa-link" aria-describedby="bib102">102</a>). These mechanisms lead to poor results of immune checkpoint inhibitors. Better understanding of these immunosuppressive mechanisms and how to counteract or suppress them has the potential to improve treatment response in prostate cancer. This will require evaluation of the tumor microenvironment and other aspects of heterogeneity, such as the immune environment, metabolism, and hypoxia, in prostate cancer. Multifaceted measures of tumor heterogeneity along with computational models to capture the interactions that drive tumor response to treatment are needed.</p>
<p>Oncogenes make strong therapeutic targets. Through mutation, upregulation, or gene fusion, oncogenes drive constitutive activation of signaling pathways and processes that lead to tumor development and progression. Shutting off the signaling caused by the dysfunctional oncogene is the goal and this often means developing a small molecule drug to disrupt or turn off the oncogene. However, when a tumor suppressor is lost, the therapeutic strategy is not as straightforward. Reactivation or upregulation of a non-mutant allele of a tumor suppressor, such as TP53, is a strategy that has proven difficult to effectively implement. Finding alternative ways to leverage the identified vulnerability, such as synthetic lethality, can be successful. For example, the synthetic lethal interaction between PARP inhibition and homologous recombination-deficient tumors has been successful in the clinic (<a href="#bib103" class="usa-link" aria-describedby="bib103">103</a>). However, determining an effective therapeutic strategy to target tumor suppressors remains a fundamental challenge in cancer biology. In prostate cancer, as we described above, the challenge is amplified by the fact that the disease is often a result of the loss of multiple tumor suppressors (<a href="#bib17" class="usa-link" aria-describedby="bib17">17</a>, <a href="#bib33" class="usa-link" aria-describedby="bib33">33</a>). New modeling approaches must be considered to account for the loss of multiple tumor suppressors, while also considering androgen signaling.</p>
<p>Finally, prostate cancer researchers recognize the unique challenges that culturing primary prostate cancer cells represents. The commonly used, tumor-derived and immortalized prostate cancer cell lines are limited when compared to other cancer types such as breast and lung cancer (<a href="#bib104" class="usa-link" aria-describedby="bib104">104</a>, <a href="#bib105" class="usa-link" aria-describedby="bib105">105</a>). In addition, the prostate cancer cell lines poorly represent the genomic diversity and loss of tumor suppressors that were previously described. Many of the cell lines that are in common use today were derived from metastasis and likely do not model the primary disease faithfully (<a href="#bib106" class="usa-link" aria-describedby="bib106">106</a>). Fundamentally, prostate cancer is defined by tissue pathology. Cell lines lack appropriate tissue morphology so cannot represent pathological diversity. Mouse models are available that provide evaluation of pathology and molecular modeling, but they remain expensive and technically challenging when more than two or three molecular alterations are modeled. Prostate cancer organoids are a newer model system with the organoids retaining histological and molecular features of the patient tumors from which they were derived (<a href="#bib107" class="usa-link" aria-describedby="bib107">107</a>, <a href="#bib108" class="usa-link" aria-describedby="bib108">108</a>). They have been used to model a wider range, including rare forms, of prostate cancer (<a href="#bib109" class="usa-link" aria-describedby="bib109">109</a>), along with providing a platform for pharmacological testing (<a href="#bib110" class="usa-link" aria-describedby="bib110">110</a>, <a href="#bib111" class="usa-link" aria-describedby="bib111">111</a>). However, they remain a challenge to culture with poor overall success rates (<a href="#bib112" class="usa-link" aria-describedby="bib112">112</a>). Tissue recombination, mixing mesenchyme with epithelium, allows for modeling components of the tumor stroma with tumor cells or tumor initiating cells. Tissue recombination is a powerful model that has the potential to dissect contributions of both the epithelium and stroma in tumorigenesis, aggressiveness, and tissue pathology. Tissue recombinant models have been developed for human, mouse and rat. Mouse stem cell lines can be genetically engineered <em>in vitro</em> with multiple drivers and modeled <em>in vivo</em> by tissue recombination (<a href="#bib113" class="usa-link" aria-describedby="bib113">113</a>, <a href="#bib114" class="usa-link" aria-describedby="bib114">114</a>, <a href="#bib115" class="usa-link" aria-describedby="bib115">115</a>, <a href="#bib116" class="usa-link" aria-describedby="bib116">116</a>). Mouse syngeneic models have the added advantage of the ability to model how epithelium and stroma affect the immune microenvironment. To date, tissue recombinant models are underutilized, primarily due to technical challenges that limit the number of laboratories worldwide with the expertise in the models.</p></section><section id="sec1-6"><h2 class="pmc_sec_title">Opportunities for systems biology to advance prostate cancer research in the future</h2>
<p>Cancer systems biology approaches provide a comprehensive, data-driven framework to study and model multi-scale complexities of cancer. Many cancer types, including breast, lung, colorectal, and melanoma, have benefited from these systems-level approaches, and the successes in these cancer types offer templates or paths that can be applied to advancing prostate cancer research. These approaches can help bridge the gap between prostate cancer pathology and the molecular features driving the disease, evaluate immunotherapy potential, identify bypass mechanisms in androgen signaling, predict when treatment resistance might arise, and link these models with clinical data to better understand prostate cancer development, progression and treatment response (<a href="#fig3" class="usa-link">Fig. 3</a>).</p>
<figure class="fig xbox font-sm" id="fig3"><h3 class="obj_head">Figure 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7997/12372069/a8a1ab510fca/ERC-25-0067fig3.jpg" loading="lazy" height="304" width="661" alt="Figure 3"></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Biological challenges in prostate cancer research and the associated systems biology modeling approaches that can be used to address those challenges.</p></figcaption></figure><p>In breast cancer, molecular subtypes are used to identify therapeutic options for patients (<a href="#bib117" class="usa-link" aria-describedby="bib117">117</a>, <a href="#bib118" class="usa-link" aria-describedby="bib118">118</a>, <a href="#bib119" class="usa-link" aria-describedby="bib119">119</a>). By integrating multi-omics data, researchers have refined the classification of breast cancer into distinct subtypes, enabling more precise and personalized therapeutic options. Systems approaches have also identified mechanisms of resistance to therapies such as HER2 inhibitors and hormone therapies, facilitating the development of combination treatments. As discussed, associations between pathology and molecular drivers are complicated by tumor heterogeneity and the multi-hit nature of prostate cancer. Advancing our understanding of the molecular features that drive aggressive disease development will likely require integrating data on SNVs, protein expression, and other molecular features, along with histopathological characteristics of prostate tumors. This more comprehensive modeling of prostate cancer has the potential to better identify patients responsive to standard treatments and identify novel treatment options.</p>
<p>Systems approaches have been used to model the tumor microenvironment and identify cellular patterns related to immunotherapy response (<a href="#bib120" class="usa-link" aria-describedby="bib120">120</a>). Despite limited success with immune checkpoint inhibitors in prostate cancer, novel tools, technologies, and systems biology modeling can be used to study the immune microenvironment in prostate cancer, potentially helping to identify the immunosuppressive mechanisms that limit therapeutic efficacy (<a href="#bib102" class="usa-link" aria-describedby="bib102">102</a>). Spatial transcriptome and proteome technologies are being used to define the cell types, signaling patterns, and spatial organization of the tumor microenvironment in immune checkpoint responsive and resistant tumors (<a href="#bib121" class="usa-link" aria-describedby="bib121">121</a>), leading to new insights into how resistant tumors evolve. For example, B and T cell signatures associated with acquired resistance have been defined (<a href="#bib122" class="usa-link" aria-describedby="bib122">122</a>), and the amount of tumor-associated macrophages and gene expression programs that drive this upregulation has been associated with immunotherapy resistance (<a href="#bib123" class="usa-link" aria-describedby="bib123">123</a>). There are many other factors that play into immunotherapy response, including non-immune cell stromal content (e.g., cancer associated fibroblasts), tumor mutation burden, microsatellite instability, and checkpoint target protein expression data (<a href="#bib124" class="usa-link" aria-describedby="bib124">124</a>, <a href="#bib125" class="usa-link" aria-describedby="bib125">125</a>, <a href="#bib126" class="usa-link" aria-describedby="bib126">126</a>). Leveraging this information, along with the spatial transcriptome and proteome data, tumor microenvironment models of interactions between tumor cells and the tumor microenvironment can be built in prostate cancer to identify potential vulnerabilities for immunotherapies (<a href="#bib127" class="usa-link" aria-describedby="bib127">127</a>, <a href="#bib128" class="usa-link" aria-describedby="bib128">128</a>, <a href="#bib129" class="usa-link" aria-describedby="bib129">129</a>, <a href="#bib130" class="usa-link" aria-describedby="bib130">130</a>).</p>
<p>As discussed, an active area of prostate cancer research is to determine the bypass mechanisms of androgen receptor signaling that inevitably arise when therapeutically targeted. Signaling pathways have been extensively modeled across cancer types (<a href="#bib131" class="usa-link" aria-describedby="bib131">131</a>). Systems approaches can similarly be used in prostate cancer to model and predict how AR mutations, AR amplifications, AR variants, or alternative signaling pathways facilitate therapy resistance. By modeling these networks, novel therapeutic targets could be identified that are aimed at overcoming resistance to ADT and other androgen receptor signaling inhibitors. Similar to the work by West <em>et al.</em> (<a href="#bib68" class="usa-link" aria-describedby="bib68">68</a>, <a href="#bib74" class="usa-link" aria-describedby="bib74">74</a>), these targets could then be tested <em>in silico</em> to evaluate the potential benefits of single drug or drug combinations. Extensive follow-up work would be required to determine the viability of such novel treatments, but the potential exists for advancing systems-level models in this space.</p>
<p>Looking forward, cancer systems biology approaches hold promise in helping to advance prostate cancer research by providing a more integrated and holistic view of the disease. These approaches can be used to address the many challenges in understanding the link between genetics and pathology, and identify modes of treatment resistance and response, all with the goal of improving outcomes and survival rates for prostate cancer patients.</p></section><section id="sec8"><h2 class="pmc_sec_title">Declaration of interest</h2>
<p>LG receives research funding to her institution from Pfizer, Johnson &amp; Johnson, and Merck. All authors drafted and edited the manuscript.</p></section><section id="sec9"><h2 class="pmc_sec_title">Funding</h2>
<p>This work is partially supported by NCI grants K12CA086913 to LSG, CA262279 to SDC and CA231978 to SDC and JCC.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bib1">
<span class="label">1.</span><cite>Kreeger PK &amp; Lauffenburger DA. Cancer systems biology: a network modeling perspective. Carcinogenesis
2010. 
31
2–8. ( 10.1093/carcin/bgp261)
</cite> [<a href="https://doi.org/10.1093/carcin/bgp261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2802670/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19861649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Carcinogenesis&amp;title=Cancer%20systems%20biology:%20a%20network%20modeling%20perspective&amp;volume=31&amp;publication_year=2010&amp;pages=2-8&amp;pmid=19861649&amp;doi=10.1093/carcin/bgp261&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib2">
<span class="label">2.</span><cite>Werner HM, Mills G &amp; Ram PT. Cancer systems biology: a peek into the future of patient care?
Nat Rev Clin Oncol
2014. 
11
167–176. ( 10.1038/nrclinonc.2014.6)
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2014.6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4321721/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24492837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Cancer%20systems%20biology:%20a%20peek%20into%20the%20future%20of%20patient%20care?&amp;volume=11&amp;publication_year=2014&amp;pages=167-176&amp;pmid=24492837&amp;doi=10.1038/nrclinonc.2014.6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib3">
<span class="label">3.</span><cite>Du W &amp; Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene
2015. 
34
3215–3225. ( 10.1038/onc.2014.291)
</cite> [<a href="https://doi.org/10.1038/onc.2014.291" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25220419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Cancer%20systems%20biology:%20embracing%20complexity%20to%20develop%20better%20anticancer%20therapeutic%20strategies&amp;volume=34&amp;publication_year=2015&amp;pages=3215-3225&amp;pmid=25220419&amp;doi=10.1038/onc.2014.291&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib4">
<span class="label">4.</span><cite>Janes KA &amp; Lazzara MJ. Systems biology of the cancer cell. Annu Rev Biomed Eng
2025. 
27
1–28. ( 10.1146/annurev-bioeng-103122-030552)
</cite> [<a href="https://doi.org/10.1146/annurev-bioeng-103122-030552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39689262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Biomed%20Eng&amp;title=Systems%20biology%20of%20the%20cancer%20cell&amp;volume=27&amp;publication_year=2025&amp;pages=1-28&amp;pmid=39689262&amp;doi=10.1146/annurev-bioeng-103122-030552&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib5">
<span class="label">5.</span><cite>Baysoy A, Bai Z, Satija R, et al. 
The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol
2023. 
24
695–713. ( 10.1038/s41580-023-00615-w)
</cite> [<a href="https://doi.org/10.1038/s41580-023-00615-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10242609/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37280296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Mol%20Cell%20Biol&amp;title=The%20technological%20landscape%20and%20applications%20of%20single-cell%20multi-omics&amp;volume=24&amp;publication_year=2023&amp;pages=695-713&amp;pmid=37280296&amp;doi=10.1038/s41580-023-00615-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib6">
<span class="label">6.</span><cite>Mund A, Brunner A-D &amp; Mann M. Unbiased spatial proteomics with single-cell resolution in tissues. Mol Cell
2022. 
82
2335–2349. ( 10.1016/j.molcel.2022.05.022)
</cite> [<a href="https://doi.org/10.1016/j.molcel.2022.05.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35714588/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cell&amp;title=Unbiased%20spatial%20proteomics%20with%20single-cell%20resolution%20in%20tissues&amp;volume=82&amp;publication_year=2022&amp;pages=2335-2349&amp;pmid=35714588&amp;doi=10.1016/j.molcel.2022.05.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib7">
<span class="label">7.</span><cite>Udyavar AR, Wooten DJ, Hoeksema M, et al. 
Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res
2017. 
77
1063–1074. ( 10.1158/0008-5472.can-16-1467)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-16-1467" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5532541/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27932399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Novel%20hybrid%20phenotype%20revealed%20in%20small%20cell%20lung%20cancer%20by%20a%20transcription%20factor%20network%20model%20that%20can%20explain%20tumor%20heterogeneity&amp;volume=77&amp;publication_year=2017&amp;pages=1063-1074&amp;pmid=27932399&amp;doi=10.1158/0008-5472.can-16-1467&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib8">
<span class="label">8.</span><cite>Zhang J, Cunningham JJ, Brown JS, et al. 
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat Commun
2017. 
8
1816. ( 10.1038/s41467-017-01968-5)
</cite> [<a href="https://doi.org/10.1038/s41467-017-01968-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5703947/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29180633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Integrating%20evolutionary%20dynamics%20into%20treatment%20of%20metastatic%20castrate-resistant%20prostate%20cancer&amp;volume=8&amp;publication_year=2017&amp;pages=1816&amp;pmid=29180633&amp;doi=10.1038/s41467-017-01968-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib9">
<span class="label">9.</span><cite>Enriquez-Navas PM, Wojtkowiak JW &amp; Gatenby RA. Application of evolutionary principles to cancer therapy. Cancer Res
2015. 
75
4675–4680. ( 10.1158/0008-5472.can-15-1337)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-15-1337" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4693617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26527288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Application%20of%20evolutionary%20principles%20to%20cancer%20therapy&amp;volume=75&amp;publication_year=2015&amp;pages=4675-4680&amp;pmid=26527288&amp;doi=10.1158/0008-5472.can-15-1337&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib10">
<span class="label">10.</span><cite>Montagud A, Béal J, Tobalina L, et al. 
Patient-specific Boolean models of signalling networks guide personalised treatments. Elife
2022. 
11
e72626. ( 10.7554/eLife.72626)
</cite> [<a href="https://doi.org/10.7554/eLife.72626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9018074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35164900/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=Patient-specific%20Boolean%20models%20of%20signalling%20networks%20guide%20personalised%20treatments&amp;volume=11&amp;publication_year=2022&amp;pages=e72626&amp;pmid=35164900&amp;doi=10.7554/eLife.72626&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib11">
<span class="label">11.</span><cite>Shankar E, Weis MC, Avva J, et al. 
Complex systems biology approach in connecting PI3K-Akt and NF-κB pathways in prostate cancer. Cells
2019. 
8
201. ( 10.3390/cells8030201)
</cite> [<a href="https://doi.org/10.3390/cells8030201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6468646/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30813597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Complex%20systems%20biology%20approach%20in%20connecting%20PI3K-Akt%20and%20NF-%CE%BAB%20pathways%20in%20prostate%20cancer&amp;volume=8&amp;publication_year=2019&amp;pages=201&amp;pmid=30813597&amp;doi=10.3390/cells8030201&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib12">
<span class="label">12.</span><cite>Phan T, Crook SM, Bryce AH, et al. 
Review: mathematical modeling of prostate cancer and clinical application. Appl Sci
2020. 
10
2721. ( 10.3390/app10082721)</cite> [<a href="https://doi.org/10.3390/app10082721" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Appl%20Sci&amp;title=Review:%20mathematical%20modeling%20of%20prostate%20cancer%20and%20clinical%20application&amp;volume=10&amp;publication_year=2020&amp;pages=2721&amp;doi=10.3390/app10082721&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib13">
<span class="label">13.</span><cite>Lorenzo G, Pérez-García VM, Mariño A, et al. 
Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome. J R Soc Interface
2019. 
16
20190195. ( 10.1098/rsif.2019.0195)
</cite> [<a href="https://doi.org/10.1098/rsif.2019.0195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6731509/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31409240/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20R%20Soc%20Interface&amp;title=Mechanistic%20modelling%20of%20prostate-specific%20antigen%20dynamics%20shows%20potential%20for%20personalized%20prediction%20of%20radiation%20therapy%20outcome&amp;volume=16&amp;publication_year=2019&amp;pages=20190195&amp;pmid=31409240&amp;doi=10.1098/rsif.2019.0195&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib14">
<span class="label">14.</span><cite>Peng H, Zhao W, Tan H, et al. 
Prediction of treatment efficacy for prostate cancer using a mathematical model. Sci Rep
2016. 
6
21599. ( 10.1038/srep21599)
</cite> [<a href="https://doi.org/10.1038/srep21599" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4751505/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26868634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Prediction%20of%20treatment%20efficacy%20for%20prostate%20cancer%20using%20a%20mathematical%20model&amp;volume=6&amp;publication_year=2016&amp;pages=21599&amp;pmid=26868634&amp;doi=10.1038/srep21599&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib15">
<span class="label">15.</span><cite>Ferlay J, Colombet M, Soerjomataram I, et al. 
Cancer statistics for the year 2020: an overview. Int J Cancer
2021. 
149
778–789. ( 10.1002/ijc.33588)</cite> [<a href="https://doi.org/10.1002/ijc.33588" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33818764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=Cancer%20statistics%20for%20the%20year%202020:%20an%20overview&amp;volume=149&amp;publication_year=2021&amp;pages=778-789&amp;pmid=33818764&amp;doi=10.1002/ijc.33588&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib16">
<span class="label">16.</span><cite>Grasso CS, Wu Y-M, Robinson DR, et al. 
The mutational landscape of lethal castration-resistant prostate cancer. Nature
2012. 
487
239–243. ( 10.1038/nature11125)
</cite> [<a href="https://doi.org/10.1038/nature11125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3396711/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22722839/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The%20mutational%20landscape%20of%20lethal%20castration-resistant%20prostate%20cancer&amp;volume=487&amp;publication_year=2012&amp;pages=239-243&amp;pmid=22722839&amp;doi=10.1038/nature11125&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib17">
<span class="label">17.</span><cite>Abida W, Armenia J, Gopalan A, et al. 
Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol
2017. 
2017
1–16. ( 10.1200/po.17.00029).</cite> [<a href="https://doi.org/10.1200/po.17.00029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5558263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28825054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis%20Oncol&amp;title=Prospective%20genomic%20profiling%20of%20prostate%20cancer%20across%20disease%20states%20reveals%20germline%20and%20somatic%20alterations%20that%20may%20affect%20clinical%20decision%20making&amp;volume=2017&amp;publication_year=2017&amp;pages=1-16&amp;pmid=28825054&amp;doi=10.1200/po.17.00029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib18">
<span class="label">18.</span><cite>Armenia J, Wankowicz SAM, Liu D, et al. 
The long tail of oncogenic drivers in prostate cancer. Nat Genet
2018. 
50
645–651. ( 10.1038/s41588-018-0078-z)
</cite> [<a href="https://doi.org/10.1038/s41588-018-0078-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6107367/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29610475/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=The%20long%20tail%20of%20oncogenic%20drivers%20in%20prostate%20cancer&amp;volume=50&amp;publication_year=2018&amp;pages=645-651&amp;pmid=29610475&amp;doi=10.1038/s41588-018-0078-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib19">
<span class="label">19.</span><cite>Robinson D, Van Allen EM, Wu Y-M, et al. 
Integrative clinical genomics of advanced prostate cancer. Cell
2015. 
162
454. ( 10.1016/j.cell.2015.06.053)
</cite> [<a href="https://doi.org/10.1016/j.cell.2015.06.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28843286/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Integrative%20clinical%20genomics%20of%20advanced%20prostate%20cancer&amp;volume=162&amp;publication_year=2015&amp;pages=454&amp;pmid=28843286&amp;doi=10.1016/j.cell.2015.06.053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib20">
<span class="label">20.</span><cite>Barbieri CE, Baca SC, Lawrence MS, et al. 
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet
2012. 
44
685–689. ( 10.1038/ng.2279)
</cite> [<a href="https://doi.org/10.1038/ng.2279" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3673022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22610119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Exome%20sequencing%20identifies%20recurrent%20SPOP,%20FOXA1%20and%20MED12%20mutations%20in%20prostate%20cancer&amp;volume=44&amp;publication_year=2012&amp;pages=685-689&amp;pmid=22610119&amp;doi=10.1038/ng.2279&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib21">
<span class="label">21.</span><cite>Baca SC, Prandi D, Lawrence MS, et al. 
Punctuated evolution of prostate cancer genomes. Cell
2013. 
153
666–677. ( 10.1016/j.cell.2013.03.021)
</cite> [<a href="https://doi.org/10.1016/j.cell.2013.03.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3690918/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23622249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Punctuated%20evolution%20of%20prostate%20cancer%20genomes&amp;volume=153&amp;publication_year=2013&amp;pages=666-677&amp;pmid=23622249&amp;doi=10.1016/j.cell.2013.03.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib22">
<span class="label">22.</span><cite>Fraser M, Sabelnykova VY, Yamaguchi TN, et al. 
Genomic hallmarks of localized, non-indolent prostate cancer. Nature
2017. 
541
359–364. ( 10.1038/nature20788)
</cite> [<a href="https://doi.org/10.1038/nature20788" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28068672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Genomic%20hallmarks%20of%20localized,%20non-indolent%20prostate%20cancer&amp;volume=541&amp;publication_year=2017&amp;pages=359-364&amp;pmid=28068672&amp;doi=10.1038/nature20788&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib23">
<span class="label">23.</span><cite>Stopsack KH, Nandakumar S, Arora K, et al. 
Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res
2022. 
28
318–326. ( 10.1158/1078-0432.ccr-21-2577)
</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-21-2577" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8776579/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34667026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Differences%20in%20prostate%20cancer%20genomes%20by%20self-reported%20race:%20contributions%20of%20genetic%20ancestry,%20modifiable%20cancer%20risk%20factors,%20and%20clinical%20factors&amp;volume=28&amp;publication_year=2022&amp;pages=318-326&amp;pmid=34667026&amp;doi=10.1158/1078-0432.ccr-21-2577&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib24">
<span class="label">24.</span><cite>Laajala TD, Sreekanth V, Soupir AC, et al. 
A harmonized resource of integrated prostate cancer clinical, -omic, and signature features. Sci Data
2023. 
10
430. ( 10.1038/s41597-023-02335-4)
</cite> [<a href="https://doi.org/10.1038/s41597-023-02335-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10322899/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37407670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Data&amp;title=A%20harmonized%20resource%20of%20integrated%20prostate%20cancer%20clinical,%20-omic,%20and%20signature%20features&amp;volume=10&amp;publication_year=2023&amp;pages=430&amp;pmid=37407670&amp;doi=10.1038/s41597-023-02335-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib25">
<span class="label">25.</span><cite>Taylor BS, Schultz N, Hieronymus H, et al. 
Integrative genomic profiling of human prostate cancer. Cancer Cell
2010. 
18
11–22. ( 10.1016/j.ccr.2010.05.026)
</cite> [<a href="https://doi.org/10.1016/j.ccr.2010.05.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3198787/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20579941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Integrative%20genomic%20profiling%20of%20human%20prostate%20cancer&amp;volume=18&amp;publication_year=2010&amp;pages=11-22&amp;pmid=20579941&amp;doi=10.1016/j.ccr.2010.05.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib26">
<span class="label">26.</span><cite>Abeshouse A, Ahn J, Akbani R, et al. 
The molecular taxonomy of primary prostate cancer. Cell
2015. 
163
1011–1025. ( 10.1016/j.cell.2015.10.025)
</cite> [<a href="https://doi.org/10.1016/j.cell.2015.10.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4695400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26544944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20molecular%20taxonomy%20of%20primary%20prostate%20cancer&amp;volume=163&amp;publication_year=2015&amp;pages=1011-1025&amp;pmid=26544944&amp;doi=10.1016/j.cell.2015.10.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib27">
<span class="label">27.</span><cite>Herlemann A, Huang H-C, Alam R, et al. 
Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis
2020. 
23
136–143. ( 10.1038/s41391-019-0167-9)
</cite> [<a href="https://doi.org/10.1038/s41391-019-0167-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8076042/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31455846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate%20Cancer%20Prostatic%20Dis&amp;title=Decipher%20identifies%20men%20with%20otherwise%20clinically%20favorable-intermediate%20risk%20disease%20who%20may%20not%20be%20good%20candidates%20for%20active%20surveillance&amp;volume=23&amp;publication_year=2020&amp;pages=136-143&amp;pmid=31455846&amp;doi=10.1038/s41391-019-0167-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib28">
<span class="label">28.</span><cite>Knezevic D, Goddard AD, Natraj N, et al. 
Analytical validation of the oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genom
2013. 
14
690. ( 10.1186/1471-2164-14-690)</cite> [<a href="https://doi.org/10.1186/1471-2164-14-690" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4007703/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24103217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Genom&amp;title=Analytical%20validation%20of%20the%20oncotype%20DX%20prostate%20cancer%20assay%20%E2%80%93%20a%20clinical%20RT-PCR%20assay%20optimized%20for%20prostate%20needle%20biopsies&amp;volume=14&amp;publication_year=2013&amp;pages=690&amp;pmid=24103217&amp;doi=10.1186/1471-2164-14-690&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib29">
<span class="label">29.</span><cite>NICE . NICE advice – prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) prolaris gene expression assay for assessing long-term risk of prostate cancer progression. BJU Int
2018. 
122
173–180. ( 10.1111/bju.14452)
</cite> [<a href="https://doi.org/10.1111/bju.14452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30134062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BJU%20Int&amp;title=NICE%20advice%20%E2%80%93%20prolaris%20gene%20expression%20assay%20for%20assessing%20long-term%20risk%20of%20prostate%20cancer%20progression:%20%C2%A9%20NICE%20(2016)%20prolaris%20gene%20expression%20assay%20for%20assessing%20long-term%20risk%20of%20prostate%20cancer%20progression&amp;volume=122&amp;publication_year=2018&amp;pages=173-180&amp;pmid=30134062&amp;doi=10.1111/bju.14452&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib30">
<span class="label">30.</span><cite>Tomlins SA, Rhodes DR, Perner S, et al. 
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
2005. 
310
644–648. ( 10.1126/science.1117679)
</cite> [<a href="https://doi.org/10.1126/science.1117679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16254181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Recurrent%20fusion%20of%20TMPRSS2%20and%20ETS%20transcription%20factor%20genes%20in%20prostate%20cancer&amp;volume=310&amp;publication_year=2005&amp;pages=644-648&amp;pmid=16254181&amp;doi=10.1126/science.1117679&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib31">
<span class="label">31.</span><cite>Magi-Galluzzi C, Tsusuki T, Elson P, et al. 
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate
2011. 
71
489–497. ( 10.1002/pros.21265)
</cite> [<a href="https://doi.org/10.1002/pros.21265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20878952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=TMPRSS2-ERG%20gene%20fusion%20prevalence%20and%20class%20are%20significantly%20different%20in%20prostate%20cancer%20of%20Caucasian,%20African-American%20and%20Japanese%20patients&amp;volume=71&amp;publication_year=2011&amp;pages=489-497&amp;pmid=20878952&amp;doi=10.1002/pros.21265&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib32">
<span class="label">32.</span><cite>Hieronymus H, Schultz N, Gopalan A, et al. 
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A
2014. 
111
11139–11144. ( 10.1073/pnas.1411446111)
</cite> [<a href="https://doi.org/10.1073/pnas.1411446111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4121784/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25024180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Copy%20number%20alteration%20burden%20predicts%20prostate%20cancer%20relapse&amp;volume=111&amp;publication_year=2014&amp;pages=11139-11144&amp;pmid=25024180&amp;doi=10.1073/pnas.1411446111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib33">
<span class="label">33.</span><cite>Orman MV, Sreekanth V, Laajala TD, et al. 
ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer. Front Pharmacol
2024. 
15
1360352. ( 10.3389/fphar.2024.1360352)
</cite> [<a href="https://doi.org/10.3389/fphar.2024.1360352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11094266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38751776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=ProstaMine:%20a%20bioinformatics%20tool%20for%20identifying%20subtype-specific%20co-alterations%20associated%20with%20aggressiveness%20in%20prostate%20cancer&amp;volume=15&amp;publication_year=2024&amp;pages=1360352&amp;pmid=38751776&amp;doi=10.3389/fphar.2024.1360352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib34">
<span class="label">34.</span><cite>Espiritu SMG, Liu LY, Rubanova Y, et al. 
The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell
2018. 
173
1003–1013.e15. ( 10.1016/j.cell.2018.03.029)
</cite> [<a href="https://doi.org/10.1016/j.cell.2018.03.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29681457/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20evolutionary%20landscape%20of%20localized%20prostate%20cancers%20drives%20clinical%20aggression&amp;volume=173&amp;publication_year=2018&amp;pages=1003-1013.e15&amp;pmid=29681457&amp;doi=10.1016/j.cell.2018.03.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib35">
<span class="label">35.</span><cite>Abdulkadir SA, Magee JA, Peters TJ, et al. 
Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol
2002. 
22
1495–1503. ( 10.1128/mcb.22.5.1495-1503.2002)
</cite> [<a href="https://doi.org/10.1128/mcb.22.5.1495-1503.2002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC134699/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11839815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cell%20Biol&amp;title=Conditional%20loss%20of%20Nkx3.1%20in%20adult%20mice%20induces%20prostatic%20intraepithelial%20neoplasia&amp;volume=22&amp;publication_year=2002&amp;pages=1495-1503&amp;pmid=11839815&amp;doi=10.1128/mcb.22.5.1495-1503.2002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib36">
<span class="label">36.</span><cite>Wu M, Shi L, Cimic A, et al. 
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res
2012. 
72
2833–2843. ( 10.1158/0008-5472.can-11-2724)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-11-2724" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3654674/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22467172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Suppression%20of%20Tak1%20promotes%20prostate%20tumorigenesis&amp;volume=72&amp;publication_year=2012&amp;pages=2833-2843&amp;pmid=22467172&amp;doi=10.1158/0008-5472.can-11-2724&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib37">
<span class="label">37.</span><cite>Jillson LK, Rider LC, Rodrigues LU, et al. 
MAP3K7 loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate cancer with joint loss of CHD1. Mol Cancer Res
2021. 
19
1123–1136. ( 10.1158/1541-7786.mcr-20-0913)
</cite> [<a href="https://doi.org/10.1158/1541-7786.mcr-20-0913" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8254790/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33846123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer%20Res&amp;title=MAP3K7%20loss%20drives%20enhanced%20androgen%20signaling%20and%20independently%20confers%20risk%20of%20recurrence%20in%20prostate%20cancer%20with%20joint%20loss%20of%20CHD1&amp;volume=19&amp;publication_year=2021&amp;pages=1123-1136&amp;pmid=33846123&amp;doi=10.1158/1541-7786.mcr-20-0913&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib38">
<span class="label">38.</span><cite>Cairns P, Okami K, Halachmi S, et al. 
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res
1997. 
57
4997–5000.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9371490/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Frequent%20inactivation%20of%20PTEN/MMAC1%20in%20primary%20prostate%20cancer&amp;volume=57&amp;publication_year=1997&amp;pages=4997-5000&amp;pmid=9371490&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib39">
<span class="label">39.</span><cite>Wang S, Gao J, Lei Q, et al. 
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell
2003. 
4
209–221. ( 10.1016/s1535-6108(03)00215-0)
</cite> [<a href="https://doi.org/10.1016/s1535-6108(03)00215-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14522255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Prostate-specific%20deletion%20of%20the%20murine%20Pten%20tumor%20suppressor%20gene%20leads%20to%20metastatic%20prostate%20cancer&amp;volume=4&amp;publication_year=2003&amp;pages=209-221&amp;pmid=14522255&amp;doi=10.1016/s1535-6108(03)00215-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib40">
<span class="label">40.</span><cite>Augello MA, Liu D, Deonarine LD, et al. 
CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell
2019. 
35
817–819. ( 10.1016/j.ccell.2019.04.012)
</cite> [<a href="https://doi.org/10.1016/j.ccell.2019.04.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31085180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=CHD1%20loss%20alters%20AR%20binding%20at%20lineage-specific%20enhancers%20and%20modulates%20distinct%20transcriptional%20programs%20to%20drive%20prostate%20tumorigenesis&amp;volume=35&amp;publication_year=2019&amp;pages=817-819&amp;pmid=31085180&amp;doi=10.1016/j.ccell.2019.04.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib41">
<span class="label">41.</span><cite>Boysen G, Barbieri CE, Prandi D, et al. 
SPOP mutation leads to genomic instability in prostate cancer. Elife
2015. 
4
e09207. ( 10.7554/eLife.09207)
</cite> [<a href="https://doi.org/10.7554/eLife.09207" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4621745/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26374986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=SPOP%20mutation%20leads%20to%20genomic%20instability%20in%20prostate%20cancer&amp;volume=4&amp;publication_year=2015&amp;pages=e09207&amp;pmid=26374986&amp;doi=10.7554/eLife.09207&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib42">
<span class="label">42.</span><cite>Alsheikh B, Chegondi M &amp; Totapally B. Platelet transfusion thresholds among children admitted to a pediatric intensive care unit. Cureus
2017. 
9
e1797. ( 10.7759/cureus.1797)
</cite> [<a href="https://doi.org/10.7759/cureus.1797" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5741280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29282441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cureus&amp;title=Platelet%20transfusion%20thresholds%20among%20children%20admitted%20to%20a%20pediatric%20intensive%20care%20unit&amp;volume=9&amp;publication_year=2017&amp;pages=e1797&amp;pmid=29282441&amp;doi=10.7759/cureus.1797&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib43">
<span class="label">43.</span><cite>Abida W, Cyrta J, Heller G, et al. 
Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A
2019. 
116
11428–11436. ( 10.1073/pnas.1902651116)
</cite> [<a href="https://doi.org/10.1073/pnas.1902651116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6561293/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31061129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Genomic%20correlates%20of%20clinical%20outcome%20in%20advanced%20prostate%20cancer&amp;volume=116&amp;publication_year=2019&amp;pages=11428-11436&amp;pmid=31061129&amp;doi=10.1073/pnas.1902651116&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib44">
<span class="label">44.</span><cite>Yamada Y &amp; Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep
2021. 
23
15. ( 10.1007/s11912-020-01003-9)
</cite> [<a href="https://doi.org/10.1007/s11912-020-01003-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7990389/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33433737/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol%20Rep&amp;title=Clinical%20and%20biological%20features%20of%20neuroendocrine%20prostate%20cancer&amp;volume=23&amp;publication_year=2021&amp;pages=15&amp;pmid=33433737&amp;doi=10.1007/s11912-020-01003-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib45">
<span class="label">45.</span><cite>Beltran H, Tomlins S, Aparicio A, et al. 
Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res
2014. 
20
2846–2850. ( 10.1158/1078-0432.ccr-13-3309)
</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-13-3309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4040316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24727321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Aggressive%20variants%20of%20castration-resistant%20prostate%20cancer&amp;volume=20&amp;publication_year=2014&amp;pages=2846-2850&amp;pmid=24727321&amp;doi=10.1158/1078-0432.ccr-13-3309&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib46">
<span class="label">46.</span><cite>Labrecque MP, Coleman IM, Brown LG, et al. 
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Investig
2019. 
129
4492–4505. ( 10.1172/jci128212)
</cite> [<a href="https://doi.org/10.1172/jci128212" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6763249/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31361600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=Molecular%20profiling%20stratifies%20diverse%20phenotypes%20of%20treatment-refractory%20metastatic%20castration-resistant%20prostate%20cancer&amp;volume=129&amp;publication_year=2019&amp;pages=4492-4505&amp;pmid=31361600&amp;doi=10.1172/jci128212&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib47">
<span class="label">47.</span><cite>Abate-Shen C, Banach-Petrosky WA, Sun X, et al. 
Nkx3.1; pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res
2003. 
63
3886–3890.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/12873978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Nkx3.1;%20pten%20mutant%20mice%20develop%20invasive%20prostate%20adenocarcinoma%20and%20lymph%20node%20metastases&amp;volume=63&amp;publication_year=2003&amp;pages=3886-3890&amp;pmid=12873978&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib48">
<span class="label">48.</span><cite>Bowen C, Ostrowski MC, Leone G, et al. 
Loss of PTEN accelerates NKX3.1 degradation to promote prostate cancer progression. Cancer Res
2019. 
79
4124–4134. ( 10.1158/0008-5472.can-18-4110)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-18-4110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6753942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31213464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Loss%20of%20PTEN%20accelerates%20NKX3.1%20degradation%20to%20promote%20prostate%20cancer%20progression&amp;volume=79&amp;publication_year=2019&amp;pages=4124-4134&amp;pmid=31213464&amp;doi=10.1158/0008-5472.can-18-4110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib49">
<span class="label">49.</span><cite>Ku SY, Rosario S, Wang Y, et al. 
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science
2017. 
355
78–83. ( 10.1126/science.aah4199)
</cite> [<a href="https://doi.org/10.1126/science.aah4199" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5367887/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28059767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Rb1%20and%20Trp53%20cooperate%20to%20suppress%20prostate%20cancer%20lineage%20plasticity,%20metastasis,%20and%20antiandrogen%20resistance&amp;volume=355&amp;publication_year=2017&amp;pages=78-83&amp;pmid=28059767&amp;doi=10.1126/science.aah4199&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib50">
<span class="label">50.</span><cite>Di Cristofano A, Pesce B, Cordon-Cardo C, et al. 
Pten is essential for embryonic development and tumour suppression. Nat Genet
1998. 
19
348–355. ( 10.1038/1235)
</cite> [<a href="https://doi.org/10.1038/1235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9697695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Pten%20is%20essential%20for%20embryonic%20development%20and%20tumour%20suppression&amp;volume=19&amp;publication_year=1998&amp;pages=348-355&amp;pmid=9697695&amp;doi=10.1038/1235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib51">
<span class="label">51.</span><cite>Carver BS, Tran J, Gopalan A, et al. 
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet
2009. 
41
619–624. ( 10.1038/ng.370)
</cite> [<a href="https://doi.org/10.1038/ng.370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2835150/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19396168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Aberrant%20ERG%20expression%20cooperates%20with%20loss%20of%20PTEN%20to%20promote%20cancer%20progression%20in%20the%20prostate&amp;volume=41&amp;publication_year=2009&amp;pages=619-624&amp;pmid=19396168&amp;doi=10.1038/ng.370&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib52">
<span class="label">52.</span><cite>Rodrigues LU, Rider L, Nieto C, et al. 
Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res
2015. 
75
1021–1034. ( 10.1158/0008-5472.can-14-1596)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-14-1596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4531265/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25770290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Coordinate%20loss%20of%20MAP3K7%20and%20CHD1%20promotes%20aggressive%20prostate%20cancer&amp;volume=75&amp;publication_year=2015&amp;pages=1021-1034&amp;pmid=25770290&amp;doi=10.1158/0008-5472.can-14-1596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib53">
<span class="label">53.</span><cite>Yang W, Soares J, Greninger P, et al. 
Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res
2013. 
41
D955–D961. ( 10.1093/nar/gks1111)
</cite> [<a href="https://doi.org/10.1093/nar/gks1111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3531057/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23180760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=Genomics%20of%20drug%20sensitivity%20in%20cancer%20(GDSC):%20a%20resource%20for%20therapeutic%20biomarker%20discovery%20in%20cancer%20cells&amp;volume=41&amp;publication_year=2013&amp;pages=D955-D961&amp;pmid=23180760&amp;doi=10.1093/nar/gks1111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib54">
<span class="label">54.</span><cite>Fumiã HF &amp; Martins ML. Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS One
2013. 
8
e69008. ( 10.1371/journal.pone.0069008)
</cite> [<a href="https://doi.org/10.1371/journal.pone.0069008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3724878/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23922675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Boolean%20network%20model%20for%20cancer%20pathways:%20predicting%20carcinogenesis%20and%20targeted%20therapy%20outcomes&amp;volume=8&amp;publication_year=2013&amp;pages=e69008&amp;pmid=23922675&amp;doi=10.1371/journal.pone.0069008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib55">
<span class="label">55.</span><cite>Kuipers J, Thurnherr T, Moffa G, et al. 
Mutational interactions define novel cancer subgroups. Nat Commun
2018. 
9
4353. ( 10.1038/s41467-018-06867-x)
</cite> [<a href="https://doi.org/10.1038/s41467-018-06867-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6195543/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30341300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Mutational%20interactions%20define%20novel%20cancer%20subgroups&amp;volume=9&amp;publication_year=2018&amp;pages=4353&amp;pmid=30341300&amp;doi=10.1038/s41467-018-06867-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib56">
<span class="label">56.</span><cite>Blatti C, de la Fuente J, Gao H, et al. 
Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer. Cancer Res
2023. 
83
1361–1380. ( 10.1158/0008-5472.can-22-1910)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-22-1910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10102853/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36779846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Bayesian%20machine%20learning%20enables%20identification%20of%20transcriptional%20network%20disruptions%20associated%20with%20drug-resistant%20prostate%20cancer&amp;volume=83&amp;publication_year=2023&amp;pages=1361-1380&amp;pmid=36779846&amp;doi=10.1158/0008-5472.can-22-1910&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib57">
<span class="label">57.</span><cite>Prandi D, Baca SC, Romanel A, et al. 
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol
2014. 
15
439. ( 10.1186/s13059-014-0439-6)
</cite> [<a href="https://doi.org/10.1186/s13059-014-0439-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4167267/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25160065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Biol&amp;title=Unraveling%20the%20clonal%20hierarchy%20of%20somatic%20genomic%20aberrations&amp;volume=15&amp;publication_year=2014&amp;pages=439&amp;pmid=25160065&amp;doi=10.1186/s13059-014-0439-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib58">
<span class="label">58.</span><cite>Wedge DC, Gundem G, Mitchell T, et al. 
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet
2018. 
50
682–692. ( 10.1038/s41588-018-0086-z)
</cite> [<a href="https://doi.org/10.1038/s41588-018-0086-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6372064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29662167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Sequencing%20of%20prostate%20cancers%20identifies%20new%20cancer%20genes,%20routes%20of%20progression%20and%20drug%20targets&amp;volume=50&amp;publication_year=2018&amp;pages=682-692&amp;pmid=29662167&amp;doi=10.1038/s41588-018-0086-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib59">
<span class="label">59.</span><cite>Woodcock DJ, Sahli A, Teslo R, et al. 
Genomic evolution shapes prostate cancer disease type. Cell Genom
2024. 
4
100511. ( 10.1016/j.xgen.2024.100511)
</cite> [<a href="https://doi.org/10.1016/j.xgen.2024.100511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10943594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38428419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Genom&amp;title=Genomic%20evolution%20shapes%20prostate%20cancer%20disease%20type&amp;volume=4&amp;publication_year=2024&amp;pages=100511&amp;pmid=38428419&amp;doi=10.1016/j.xgen.2024.100511&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib60">
<span class="label">60.</span><cite>Liu D, Augello MA, Grbesa I, et al. 
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Investig
2021. 
131
e147878. ( 10.1172/jci147878).
</cite> [<a href="https://doi.org/10.1172/jci147878" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8121518/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33998599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Investig&amp;title=Tumor%20subtype%20defines%20distinct%20pathways%20of%20molecular%20and%20clinical%20progression%20in%20primary%20prostate%20cancer&amp;volume=131&amp;publication_year=2021&amp;pages=e147878&amp;pmid=33998599&amp;doi=10.1172/jci147878&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib61">
<span class="label">61.</span><cite>Hussain M, Tangen CM, Berry DL, et al. 
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med
2013. 
368
1314–1325. ( 10.1056/nejmoa1212299)
</cite> [<a href="https://doi.org/10.1056/nejmoa1212299" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3682658/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23550669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Intermittent%20versus%20continuous%20androgen%20deprivation%20in%20prostate%20cancer&amp;volume=368&amp;publication_year=2013&amp;pages=1314-1325&amp;pmid=23550669&amp;doi=10.1056/nejmoa1212299&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib62">
<span class="label">62.</span><cite>Freedland SJ, de Almeida Luz M, De Giorgi U, et al. 
Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med
2023. 
389
1453–1465. ( 10.1056/nejmoa2303974)
</cite> [<a href="https://doi.org/10.1056/nejmoa2303974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37851874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Improved%20outcomes%20with%20enzalutamide%20in%20biochemically%20recurrent%20prostate%20cancer&amp;volume=389&amp;publication_year=2023&amp;pages=1453-1465&amp;pmid=37851874&amp;doi=10.1056/nejmoa2303974&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib63">
<span class="label">63.</span><cite>Crook JM, O’Callaghan CJ, Duncan G, et al. 
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med
2012. 
367
895–903. ( 10.1056/nejmoa1201546)
</cite> [<a href="https://doi.org/10.1056/nejmoa1201546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3521033/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22931259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Intermittent%20androgen%20suppression%20for%20rising%20PSA%20level%20after%20radiotherapy&amp;volume=367&amp;publication_year=2012&amp;pages=895-903&amp;pmid=22931259&amp;doi=10.1056/nejmoa1201546&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib64">
<span class="label">64.</span><cite>Stanková K, Brown JS, Dalton WS, et al. 
Optimizing cancer treatment using game theory: a review. JAMA Oncol
2018. 
5
96–103. ( 10.1001/jamaoncol.2018.3395)</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.3395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6947530/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30098166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Optimizing%20cancer%20treatment%20using%20game%20theory:%20a%20review&amp;volume=5&amp;publication_year=2018&amp;pages=96-103&amp;pmid=30098166&amp;doi=10.1001/jamaoncol.2018.3395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib65">
<span class="label">65.</span><cite>Gatenby RA, Silva AS, Gillies RJ, et al. 
Adaptive therapy. Cancer Res
2009. 
69
4894–4903. ( 10.1158/0008-5472.can-08-3658)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-08-3658" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3728826/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19487300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Adaptive%20therapy&amp;volume=69&amp;publication_year=2009&amp;pages=4894-4903&amp;pmid=19487300&amp;doi=10.1158/0008-5472.can-08-3658&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib66">
<span class="label">66.</span><cite>Brady-Nicholls R, Nagy JD, Gerke TA, et al. 
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nat Commun
2020. 
11
1750. ( 10.1038/s41467-020-15424-4)
</cite> [<a href="https://doi.org/10.1038/s41467-020-15424-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7145869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32273504/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Prostate-specific%20antigen%20dynamics%20predict%20individual%20responses%20to%20intermittent%20androgen%20deprivation&amp;volume=11&amp;publication_year=2020&amp;pages=1750&amp;pmid=32273504&amp;doi=10.1038/s41467-020-15424-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib67">
<span class="label">67.</span><cite>Zhang J, Cunningham J, Brown J, et al. 
Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife
2022. 
11
e76284. ( 10.7554/elife.76284)
</cite> [<a href="https://doi.org/10.7554/elife.76284" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9239688/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35762577/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Elife&amp;title=Evolution-based%20mathematical%20models%20significantly%20prolong%20response%20to%20abiraterone%20in%20metastatic%20castrate-resistant%20prostate%20cancer%20and%20identify%20strategies%20to%20further%20improve%20outcomes&amp;volume=11&amp;publication_year=2022&amp;pages=e76284&amp;pmid=35762577&amp;doi=10.7554/elife.76284&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib68">
<span class="label">68.</span><cite>West JB, Dinh MN, Brown JS, et al. 
Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy. Clin Cancer Res
2019. 
25
4413–4421. ( 10.1158/1078-0432.ccr-19-0006)
</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-19-0006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6665681/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30992299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Multidrug%20cancer%20therapy%20in%20metastatic%20castrate-resistant%20prostate%20cancer:%20an%20evolution-based%20strategy&amp;volume=25&amp;publication_year=2019&amp;pages=4413-4421&amp;pmid=30992299&amp;doi=10.1158/1078-0432.ccr-19-0006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib69">
<span class="label">69.</span><cite>Zhang J, Gallaher J, Cunningham JJ, et al. 
A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer. Cancers
2022. 
14
5225. ( 10.3390/cancers14215225)
</cite> [<a href="https://doi.org/10.3390/cancers14215225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9656891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36358643/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=A%20phase%201b%20adaptive%20androgen%20deprivation%20therapy%20trial%20in%20metastatic%20castration%20sensitive%20prostate%20cancer&amp;volume=14&amp;publication_year=2022&amp;pages=5225&amp;pmid=36358643&amp;doi=10.3390/cancers14215225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib70">
<span class="label">70.</span><cite>Mason NT, Burkett JM, Nelson RS, et al. 
Budget impact of adaptive abiraterone therapy for castration-resistant prostate cancer. Am Health Drug Benefits
2021. 
14
15–20.
</cite> [<a href="/articles/PMC8025923/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33841621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Health%20Drug%20Benefits&amp;title=Budget%20impact%20of%20adaptive%20abiraterone%20therapy%20for%20castration-resistant%20prostate%20cancer&amp;volume=14&amp;publication_year=2021&amp;pages=15-20&amp;pmid=33841621&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib71">
<span class="label">71.</span><cite>Gatenby RA, Brown J &amp; Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res
2009. 
69
7499–7502. ( 10.1158/0008-5472.can-09-1354)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-09-1354" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19752088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Lessons%20from%20applied%20ecology:%20cancer%20control%20using%20an%20evolutionary%20double%20bind&amp;volume=69&amp;publication_year=2009&amp;pages=7499-7502&amp;pmid=19752088&amp;doi=10.1158/0008-5472.can-09-1354&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib72">
<span class="label">72.</span><cite>Gatenby RA. A change of strategy in the war on cancer. Nature
2009. 
459
508–509. ( 10.1038/459508a)
</cite> [<a href="https://doi.org/10.1038/459508a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19478766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A%20change%20of%20strategy%20in%20the%20war%20on%20cancer&amp;volume=459&amp;publication_year=2009&amp;pages=508-509&amp;pmid=19478766&amp;doi=10.1038/459508a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib73">
<span class="label">73.</span><cite>Gillies RJ, Flowers CI, Drukteinis JS, et al. 
A unifying theory of carcinogenesis, and why targeted therapy doesn’t work. Eur J Radiol
2012. 
81 (Supplement 1) S48–S50. ( 10.1016/s0720-048x(12)70018-9)
</cite> [<a href="https://doi.org/10.1016/s0720-048x(12)70018-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23083599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Radiol&amp;title=A%20unifying%20theory%20of%20carcinogenesis,%20and%20why%20targeted%20therapy%20doesn%E2%80%99t%20work&amp;volume=81&amp;issue=Supplement%201&amp;publication_year=2012&amp;pages=S48-S50&amp;pmid=23083599&amp;doi=10.1016/s0720-048x(12)70018-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib74">
<span class="label">74.</span><cite>West J, You L, Zhang J, et al. 
Towards multidrug adaptive therapy. Cancer Res
2020. 
80
1578–1589. ( 10.1158/0008-5472.can-19-2669)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-19-2669" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7307613/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31948939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Towards%20multidrug%20adaptive%20therapy&amp;volume=80&amp;publication_year=2020&amp;pages=1578-1589&amp;pmid=31948939&amp;doi=10.1158/0008-5472.can-19-2669&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib75">
<span class="label">75.</span><cite>Strobl MAR, Gallaher J, West J, et al. 
Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun Med
2022. 
2
46. ( 10.1038/s43856-022-00110-x)
</cite> [<a href="https://doi.org/10.1038/s43856-022-00110-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9053239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35603284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Commun%20Med&amp;title=Spatial%20structure%20impacts%20adaptive%20therapy%20by%20shaping%20intra-tumoral%20competition&amp;volume=2&amp;publication_year=2022&amp;pages=46&amp;pmid=35603284&amp;doi=10.1038/s43856-022-00110-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib76">
<span class="label">76.</span><cite>Frankenstein Z, Basanta D, Franco OE, et al. 
Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression. Nat Ecol Evol
2020. 
4
870–884. ( 10.1038/s41559-020-1157-y)
</cite> [<a href="https://doi.org/10.1038/s41559-020-1157-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11000594/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32393869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Ecol%20Evol&amp;title=Stromal%20reactivity%20differentially%20drives%20tumour%20cell%20evolution%20and%20prostate%20cancer%20progression&amp;volume=4&amp;publication_year=2020&amp;pages=870-884&amp;pmid=32393869&amp;doi=10.1038/s41559-020-1157-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib77">
<span class="label">77.</span><cite>Laajala TD, Gerke T, Tyekucheva S, et al. 
Modeling genetic heterogeneity of drug response and resistance in cancer. Curr Opin Syst Biol
2019. 
17
8–14. ( 10.1016/j.coisb.2019.09.003)
</cite> [<a href="https://doi.org/10.1016/j.coisb.2019.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10512436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37736115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Syst%20Biol&amp;title=Modeling%20genetic%20heterogeneity%20of%20drug%20response%20and%20resistance%20in%20cancer&amp;volume=17&amp;publication_year=2019&amp;pages=8-14&amp;pmid=37736115&amp;doi=10.1016/j.coisb.2019.09.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib78">
<span class="label">78.</span><cite>Enriquez-Navas PM, Kam Y, Das T, et al. 
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med
2016. 
8
327ra24. ( 10.1126/scitranslmed.aad7842)</cite> [<a href="https://doi.org/10.1126/scitranslmed.aad7842" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4962860/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26912903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Transl%20Med&amp;title=Exploiting%20evolutionary%20principles%20to%20prolong%20tumor%20control%20in%20preclinical%20models%20of%20breast%20cancer&amp;volume=8&amp;publication_year=2016&amp;pages=327ra24&amp;pmid=26912903&amp;doi=10.1126/scitranslmed.aad7842&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib79">
<span class="label">79.</span><cite>Sun C, Wang L, Huang S, et al. 
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature
2014. 
508
118–122. ( 10.1038/nature13121)
</cite> [<a href="https://doi.org/10.1038/nature13121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24670642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Reversible%20and%20adaptive%20resistance%20to%20BRAF(V600E)%20inhibition%20in%20melanoma&amp;volume=508&amp;publication_year=2014&amp;pages=118-122&amp;pmid=24670642&amp;doi=10.1038/nature13121&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib80">
<span class="label">80.</span><cite>Das Thakur M, Salangsang F, Landman AS, et al. 
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature
2013. 
494
251–255. ( 10.1038/nature11814)
</cite> [<a href="https://doi.org/10.1038/nature11814" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3930354/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23302800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Modelling%20vemurafenib%20resistance%20in%20melanoma%20reveals%20a%20strategy%20to%20forestall%20drug%20resistance&amp;volume=494&amp;publication_year=2013&amp;pages=251-255&amp;pmid=23302800&amp;doi=10.1038/nature11814&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib81">
<span class="label">81.</span><cite>Smalley I, Kim E, Li J, et al. 
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine
2019. 
48
178–190. ( 10.1016/j.ebiom.2019.09.023)
</cite> [<a href="https://doi.org/10.1016/j.ebiom.2019.09.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6838387/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31594749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=Leveraging%20transcriptional%20dynamics%20to%20improve%20BRAF%20inhibitor%20responses%20in%20melanoma&amp;volume=48&amp;publication_year=2019&amp;pages=178-190&amp;pmid=31594749&amp;doi=10.1016/j.ebiom.2019.09.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib82">
<span class="label">82.</span><cite>Seyedi S, Teo R, Foster L, et al. 
Testing adaptive therapy protocols using gemcitabine and capecitabine in a preclinical model of endocrine-resistant breast cancer. Cancers
2024. 
16
257. ( 10.3390/cancers16020257)
</cite> [<a href="https://doi.org/10.3390/cancers16020257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10813385/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38254748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Testing%20adaptive%20therapy%20protocols%20using%20gemcitabine%20and%20capecitabine%20in%20a%20preclinical%20model%20of%20endocrine-resistant%20breast%20cancer&amp;volume=16&amp;publication_year=2024&amp;pages=257&amp;pmid=38254748&amp;doi=10.3390/cancers16020257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib83">
<span class="label">83.</span><cite>Silva AS, Kam Y, Khin ZP, et al. 
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res
2012. 
72
6362–6370. ( 10.1158/0008-5472.can-12-2235)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-12-2235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3525750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23066036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Evolutionary%20approaches%20to%20prolong%20progression-free%20survival%20in%20breast%20cancer&amp;volume=72&amp;publication_year=2012&amp;pages=6362-6370&amp;pmid=23066036&amp;doi=10.1158/0008-5472.can-12-2235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib84">
<span class="label">84.</span><cite>Bacevic K, Noble R, Soffar A, et al. 
Spatial competition constrains resistance to targeted cancer therapy. Nat Commun
2017. 
8
1995. ( 10.1038/s41467-017-01516-1)
</cite> [<a href="https://doi.org/10.1038/s41467-017-01516-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5722825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29222471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Spatial%20competition%20constrains%20resistance%20to%20targeted%20cancer%20therapy&amp;volume=8&amp;publication_year=2017&amp;pages=1995&amp;pmid=29222471&amp;doi=10.1038/s41467-017-01516-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib85">
<span class="label">85.</span><cite>Mukherjee UA, Hockings H, Counsell N, et al. 
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. BMJ Open
2024. 
14
e091262. ( 10.1136/bmjopen-2024-091262)</cite> [<a href="https://doi.org/10.1136/bmjopen-2024-091262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11667365/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39806715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20Open&amp;title=Study%20protocol%20for%20Adaptive%20ChemoTherapy%20for%20Ovarian%20cancer%20(ACTOv):%20a%20multicentre%20phase%20II%20randomised%20controlled%20trial%20to%20evaluate%20the%20efficacy%20of%20adaptive%20therapy%20(AT)%20with%20carboplatin,%20based%20on%20changes%20in%20CA125,%20in%20patients%20with%20relapsed%20platinum-sensitive%20high-grade%20serous%20or%20high-grade%20endometrioid%20ovarian%20cancer&amp;volume=14&amp;publication_year=2024&amp;pages=e091262&amp;pmid=39806715&amp;doi=10.1136/bmjopen-2024-091262&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib86">
<span class="label">86.</span><cite>Villers A, McNeal JE, Freiha FS, et al. 
Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer
1992. 
70
2313–2318. ()
</cite> [<a href="https://doi.org/10.1002/1097-0142(19921101)70:9&amp;#x0003c;2313::aid-cncr2820700917&amp;#x0003e;3.0.co;2-t" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1382830/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Multiple%20cancers%20in%20the%20prostate.%20Morphologic%20features%20of%20clinically%20recognized%20versus%20incidental%20tumors&amp;volume=70&amp;publication_year=1992&amp;pages=2313-2318&amp;pmid=1382830&amp;doi=10.1002/1097-0142(19921101)70:9&amp;#x0003c;2313::aid-cncr2820700917&amp;#x0003e;3.0.co;2-t&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib87">
<span class="label">87.</span><cite>Boutros PC, Fraser M, Harding NJ, et al. 
Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet
2015. 
47
736–745. ( 10.1038/ng.3315)
</cite> [<a href="https://doi.org/10.1038/ng.3315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26005866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Spatial%20genomic%20heterogeneity%20within%20localized,%20multifocal%20prostate%20cancer&amp;volume=47&amp;publication_year=2015&amp;pages=736-745&amp;pmid=26005866&amp;doi=10.1038/ng.3315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib88">
<span class="label">88.</span><cite>Herberts C, Annala M, Sipola J, et al. 
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature
2022. 
608
199–208. ( 10.1038/s41586-022-04975-9)
</cite> [<a href="https://doi.org/10.1038/s41586-022-04975-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35859180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Deep%20whole-genome%20ctDNA%20chronology%20of%20treatment-resistant%20prostate%20cancer&amp;volume=608&amp;publication_year=2022&amp;pages=199-208&amp;pmid=35859180&amp;doi=10.1038/s41586-022-04975-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib89">
<span class="label">89.</span><cite>Greaves M &amp; Maley CC. Clonal evolution in cancer. Nature
2012. 
481
306–313. ( 10.1038/nature10762)
</cite> [<a href="https://doi.org/10.1038/nature10762" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3367003/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22258609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Clonal%20evolution%20in%20cancer&amp;volume=481&amp;publication_year=2012&amp;pages=306-313&amp;pmid=22258609&amp;doi=10.1038/nature10762&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib90">
<span class="label">90.</span><cite>Novysedlak R, Guney M, Al Khouri M, et al. 
The immune microenvironment in prostate cancer: a comprehensive review. Oncology
2024. 
103
1–25. ( 10.1159/000541881)</cite> [<a href="https://doi.org/10.1159/000541881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12140600/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39380471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology&amp;title=The%20immune%20microenvironment%20in%20prostate%20cancer:%20a%20comprehensive%20review&amp;volume=103&amp;publication_year=2024&amp;pages=1-25&amp;pmid=39380471&amp;doi=10.1159/000541881&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib91">
<span class="label">91.</span><cite>Zuo S, Wei M, Wang S, et al. 
Pan-cancer analysis of immune cell infiltration identifies a prognostic immune-cell characteristic score (ICCS) in lung adenocarcinoma. Front Immunol
2020. 
11
1218. ( 10.3389/fimmu.2020.01218)
</cite> [<a href="https://doi.org/10.3389/fimmu.2020.01218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7344231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32714316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Pan-cancer%20analysis%20of%20immune%20cell%20infiltration%20identifies%20a%20prognostic%20immune-cell%20characteristic%20score%20(ICCS)%20in%20lung%20adenocarcinoma&amp;volume=11&amp;publication_year=2020&amp;pages=1218&amp;pmid=32714316&amp;doi=10.3389/fimmu.2020.01218&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib92">
<span class="label">92.</span><cite>Charoentong P, Finotello F, Angelova M, et al. 
Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep
2017. 
18
248–262. ( 10.1016/j.celrep.2016.12.019)
</cite> [<a href="https://doi.org/10.1016/j.celrep.2016.12.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28052254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=Pan-cancer%20immunogenomic%20analyses%20reveal%20genotype-immunophenotype%20relationships%20and%20predictors%20of%20response%20to%20checkpoint%20blockade&amp;volume=18&amp;publication_year=2017&amp;pages=248-262&amp;pmid=28052254&amp;doi=10.1016/j.celrep.2016.12.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib93">
<span class="label">93.</span><cite>Wang I, Song L, Wang BY, et al. 
Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol
2022. 
10
210–233.
</cite> [<a href="/articles/PMC9428569/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36051616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Exp%20Urol&amp;title=Prostate%20cancer%20immunotherapy:%20a%20review%20of%20recent%20advancements%20with%20novel%20treatment%20methods%20and%20efficacy&amp;volume=10&amp;publication_year=2022&amp;pages=210-233&amp;pmid=36051616&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib94">
<span class="label">94.</span><cite>Graham LS, Montgomery B, Cheng HH, et al. 
Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLoS One
2020. 
15
e0233260. ( 10.1371/journal.pone.0233260)
</cite> [<a href="https://doi.org/10.1371/journal.pone.0233260" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7250457/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32453797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Mismatch%20repair%20deficiency%20in%20metastatic%20prostate%20cancer:%20response%20to%20PD-1%20blockade%20and%20standard%20therapies&amp;volume=15&amp;publication_year=2020&amp;pages=e0233260&amp;pmid=32453797&amp;doi=10.1371/journal.pone.0233260&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib95">
<span class="label">95.</span><cite>Camus M, Tosolini M, Mlecnik B, et al. 
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res
2009. 
69
2685–2693. ( 10.1158/0008-5472.can-08-2654)
</cite> [<a href="https://doi.org/10.1158/0008-5472.can-08-2654" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19258510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Coordination%20of%20intratumoral%20immune%20reaction%20and%20human%20colorectal%20cancer%20recurrence&amp;volume=69&amp;publication_year=2009&amp;pages=2685-2693&amp;pmid=19258510&amp;doi=10.1158/0008-5472.can-08-2654&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib96">
<span class="label">96.</span><cite>Esfahani K, Roudaia L, Buhlaiga N, et al. 
A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol
2020. 
27 (Supplement 2) S87–S97. ( 10.3747/co.27.5223)
</cite> [<a href="https://doi.org/10.3747/co.27.5223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7194005/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32368178/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol&amp;title=A%20review%20of%20cancer%20immunotherapy:%20from%20the%20past,%20to%20the%20present,%20to%20the%20future&amp;volume=27&amp;issue=Supplement%202&amp;publication_year=2020&amp;pages=S87-S97&amp;pmid=32368178&amp;doi=10.3747/co.27.5223&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib97">
<span class="label">97.</span><cite>Fridman WH, Pagès F, Sautès-Fridman C, et al. 
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer
2012. 
12
298–306. ( 10.1038/nrc3245)
</cite> [<a href="https://doi.org/10.1038/nrc3245" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22419253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=The%20immune%20contexture%20in%20human%20tumours:%20impact%20on%20clinical%20outcome&amp;volume=12&amp;publication_year=2012&amp;pages=298-306&amp;pmid=22419253&amp;doi=10.1038/nrc3245&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib98">
<span class="label">98.</span><cite>Galon J &amp; Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov
2019. 
18
197–218. ( 10.1038/s41573-018-0007-y)
</cite> [<a href="https://doi.org/10.1038/s41573-018-0007-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30610226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Drug%20Discov&amp;title=Approaches%20to%20treat%20immune%20hot,%20altered%20and%20cold%20tumours%20with%20combination%20immunotherapies&amp;volume=18&amp;publication_year=2019&amp;pages=197-218&amp;pmid=30610226&amp;doi=10.1038/s41573-018-0007-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib99">
<span class="label">99.</span><cite>Ouyang P, Wang L, Wu J, et al. 
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front Immunol
2024. 
15
1344272. ( 10.3389/fimmu.2024.1344272)
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1344272" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10965539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38545114/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Overcoming%20cold%20tumors:%20a%20combination%20strategy%20of%20immune%20checkpoint%20inhibitors&amp;volume=15&amp;publication_year=2024&amp;pages=1344272&amp;pmid=38545114&amp;doi=10.3389/fimmu.2024.1344272&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib100">
<span class="label">100.</span><cite>Liu Y-T &amp; Sun Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics
2021. 
11
5365–5386. ( 10.7150/thno.58390)
</cite> [<a href="https://doi.org/10.7150/thno.58390" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8039952/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33859752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Turning%20cold%20tumors%20into%20hot%20tumors%20by%20improving%20T-cell%20infiltration&amp;volume=11&amp;publication_year=2021&amp;pages=5365-5386&amp;pmid=33859752&amp;doi=10.7150/thno.58390&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib101">
<span class="label">101.</span><cite>Gerard CL, Delyon J, Wicky A, et al. 
Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev
2021. 
101
102227. ( 10.1016/j.ctrv.2021.102227)
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2021.102227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34656019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treat%20Rev&amp;title=Turning%20tumors%20from%20cold%20to%20inflamed%20to%20improve%20immunotherapy%20response&amp;volume=101&amp;publication_year=2021&amp;pages=102227&amp;pmid=34656019&amp;doi=10.1016/j.ctrv.2021.102227&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib102">
<span class="label">102.</span><cite>Stultz J &amp; Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis
2021. 
24
697–717. ( 10.1038/s41391-021-00340-5)
</cite> [<a href="https://doi.org/10.1038/s41391-021-00340-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8384622/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33820953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate%20Cancer%20Prostatic%20Dis&amp;title=How%20to%20turn%20up%20the%20heat%20on%20the%20cold%20immune%20microenvironment%20of%20metastatic%20prostate%20cancer&amp;volume=24&amp;publication_year=2021&amp;pages=697-717&amp;pmid=33820953&amp;doi=10.1038/s41391-021-00340-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib103">
<span class="label">103.</span><cite>Lord CJ &amp; Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science
2017. 
355
1152–1158. ( 10.1126/science.aam7344)
</cite> [<a href="https://doi.org/10.1126/science.aam7344" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6175050/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28302823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=PARP%20inhibitors:%20synthetic%20lethality%20in%20the%20clinic&amp;volume=355&amp;publication_year=2017&amp;pages=1152-1158&amp;pmid=28302823&amp;doi=10.1126/science.aam7344&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib104">
<span class="label">104.</span><cite>Garnett MJ, Edelman EJ, Heidorn SJ, et al. 
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature
2012. 
483
570–575. ( 10.1038/nature11005)
</cite> [<a href="https://doi.org/10.1038/nature11005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3349233/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22460902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Systematic%20identification%20of%20genomic%20markers%20of%20drug%20sensitivity%20in%20cancer%20cells&amp;volume=483&amp;publication_year=2012&amp;pages=570-575&amp;pmid=22460902&amp;doi=10.1038/nature11005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib105">
<span class="label">105.</span><cite>Barretina J, Caponigro G, Stransky N, et al. 
The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature
2012. 
483
603–607. ( 10.1038/nature11003)
</cite> [<a href="https://doi.org/10.1038/nature11003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3320027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22460905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The%20cancer%20cell%20line%20encyclopedia%20enables%20predictive%20modelling%20of%20anticancer%20drug%20sensitivity&amp;volume=483&amp;publication_year=2012&amp;pages=603-607&amp;pmid=22460905&amp;doi=10.1038/nature11003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib106">
<span class="label">106.</span><cite>Ahmed Z, Mosabbir W, Tandon D, et al. How clinically relevant are prostate cancer cell lines? A comprehensive characterisation and multiomics comparison. bioRxiv
2024. 
2024.03.20.585982. ( 10.1101/2024.03.20.585982)</cite> [<a href="https://doi.org/10.1101/2024.03.20.585982" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=bioRxiv&amp;title=How%20clinically%20relevant%20are%20prostate%20cancer%20cell%20lines?%20A%20comprehensive%20characterisation%20and%20multiomics%20comparison&amp;publication_year=2024&amp;pages=2024.03.20.585982&amp;doi=10.1101/2024.03.20.585982&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib107">
<span class="label">107.</span><cite>Gao D, Vela I, Sboner A, et al. 
Organoid cultures derived from patients with advanced prostate cancer. Cell
2014. 
159
176–187. ( 10.1016/j.cell.2014.08.016)
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.08.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4237931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25201530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Organoid%20cultures%20derived%20from%20patients%20with%20advanced%20prostate%20cancer&amp;volume=159&amp;publication_year=2014&amp;pages=176-187&amp;pmid=25201530&amp;doi=10.1016/j.cell.2014.08.016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib108">
<span class="label">108.</span><cite>Drost J, Karthaus WR, Gao D, et al. 
Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc
2016. 
11
347–358. ( 10.1038/nprot.2016.006)
</cite> [<a href="https://doi.org/10.1038/nprot.2016.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4793718/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26797458/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Protoc&amp;title=Organoid%20culture%20systems%20for%20prostate%20epithelial%20and%20cancer%20tissue&amp;volume=11&amp;publication_year=2016&amp;pages=347-358&amp;pmid=26797458&amp;doi=10.1038/nprot.2016.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib109">
<span class="label">109.</span><cite>Puca L, Bareja R, Prandi D, et al. 
Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun
2018. 
9
2404. ( 10.1038/s41467-018-04495-z)
</cite> [<a href="https://doi.org/10.1038/s41467-018-04495-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6008438/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29921838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Patient%20derived%20organoids%20to%20model%20rare%20prostate%20cancer%20phenotypes&amp;volume=9&amp;publication_year=2018&amp;pages=2404&amp;pmid=29921838&amp;doi=10.1038/s41467-018-04495-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib110">
<span class="label">110.</span><cite>Pamarthy S &amp; Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer
2021. 
20
125. ( 10.1186/s12943-021-01426-3)
</cite> [<a href="https://doi.org/10.1186/s12943-021-01426-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8480086/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34587953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer&amp;title=Patient%20derived%20organoids%20in%20prostate%20cancer:%20improving%20therapeutic%20efficacy%20in%20precision%20medicine&amp;volume=20&amp;publication_year=2021&amp;pages=125&amp;pmid=34587953&amp;doi=10.1186/s12943-021-01426-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib111">
<span class="label">111.</span><cite>Karkampouna S, La Manna F, Benjak A, et al. 
Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun
2021. 
12
1117. ( 10.1038/s41467-021-21300-6)
</cite> [<a href="https://doi.org/10.1038/s41467-021-21300-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7892572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33602919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Patient-derived%20xenografts%20and%20organoids%20model%20therapy%20response%20in%20prostate%20cancer&amp;volume=12&amp;publication_year=2021&amp;pages=1117&amp;pmid=33602919&amp;doi=10.1038/s41467-021-21300-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib112">
<span class="label">112.</span><cite>Servant R, Garioni M, Vlajnic T, et al. 
Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. J Pathol
2021. 
254
543–555. ( 10.1002/path.5698)
</cite> [<a href="https://doi.org/10.1002/path.5698" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8361965/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33934365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pathol&amp;title=Prostate%20cancer%20patient-derived%20organoids:%20detailed%20outcome%20from%20a%20prospective%20cohort%20of%2081%20clinical%20specimens&amp;volume=254&amp;publication_year=2021&amp;pages=543-555&amp;pmid=33934365&amp;doi=10.1002/path.5698&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib113">
<span class="label">113.</span><cite>Ishii K, Shappell SB, Matusik RJ, et al. 
Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Lab Invest
2005. 
85
1086–1103. ( 10.1038/labinvest.3700310)
</cite> [<a href="https://doi.org/10.1038/labinvest.3700310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15980886/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lab%20Invest&amp;title=Use%20of%20tissue%20recombination%20to%20predict%20phenotypes%20of%20transgenic%20mouse%20models%20of%20prostate%20carcinoma&amp;volume=85&amp;publication_year=2005&amp;pages=1086-1103&amp;pmid=15980886&amp;doi=10.1038/labinvest.3700310&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib114">
<span class="label">114.</span><cite>Barclay WW, Woodruff RD, Hall MC, et al. 
A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology
2005. 
146
13–18. ( 10.1210/en.2004-1123)
</cite> [<a href="https://doi.org/10.1210/en.2004-1123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3033046/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15471963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocrinology&amp;title=A%20system%20for%20studying%20epithelial-stromal%20interactions%20reveals%20distinct%20inductive%20abilities%20of%20stromal%20cells%20from%20benign%20prostatic%20hyperplasia%20and%20prostate%20cancer&amp;volume=146&amp;publication_year=2005&amp;pages=13-18&amp;pmid=15471963&amp;doi=10.1210/en.2004-1123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib115">
<span class="label">115.</span><cite>Zong Y, Goldstein AS &amp; Witte ON. Tissue recombination models for the study of epithelial cancer. Cold Spring Harb Protoc
2015. 
2015
pdb.top069880. ( 10.1101/pdb.top069880)
</cite> [<a href="https://doi.org/10.1101/pdb.top069880" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26631129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cold%20Spring%20Harb%20Protoc&amp;title=Tissue%20recombination%20models%20for%20the%20study%20of%20epithelial%20cancer&amp;volume=2015&amp;publication_year=2015&amp;pages=pdb.top069880&amp;pmid=26631129&amp;doi=10.1101/pdb.top069880&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib116">
<span class="label">116.</span><cite>Cunha G, Chung LW, Shannon J, et al. 
Stromal-epithelial interactions in sex differentiation. Biol Reprod
1980. 
22
19–42. ( 10.1095/biolreprod22.1.19)
</cite> [<a href="https://doi.org/10.1095/biolreprod22.1.19" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6991009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Reprod&amp;title=Stromal-epithelial%20interactions%20in%20sex%20differentiation&amp;volume=22&amp;publication_year=1980&amp;pages=19-42&amp;pmid=6991009&amp;doi=10.1095/biolreprod22.1.19&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib117">
<span class="label">117.</span><cite>Rouzier R, Perou CM, Symmans WF, et al. 
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res
2005. 
11
5678–5685. ( 10.1158/1078-0432.ccr-04-2421)
</cite> [<a href="https://doi.org/10.1158/1078-0432.ccr-04-2421" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16115903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Breast%20cancer%20molecular%20subtypes%20respond%20differently%20to%20preoperative%20chemotherapy&amp;volume=11&amp;publication_year=2005&amp;pages=5678-5685&amp;pmid=16115903&amp;doi=10.1158/1078-0432.ccr-04-2421&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib118">
<span class="label">118.</span><cite>Prat A, Pineda E, Adamo B, et al. 
Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast
2015. 
24 (Supplement 2) S26–S35. ( 10.1016/j.breast.2015.07.008)
</cite> [<a href="https://doi.org/10.1016/j.breast.2015.07.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26253814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast&amp;title=Clinical%20implications%20of%20the%20intrinsic%20molecular%20subtypes%20of%20breast%20cancer&amp;volume=24&amp;issue=Supplement%202&amp;publication_year=2015&amp;pages=S26-S35&amp;pmid=26253814&amp;doi=10.1016/j.breast.2015.07.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib119">
<span class="label">119.</span><cite>Perou CM, Sørlie T, Eisen MB, et al. 
Molecular portraits of human breast tumours. Nature
2000. 
406
747–752. ( 10.1038/35021093)
</cite> [<a href="https://doi.org/10.1038/35021093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10963602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Molecular%20portraits%20of%20human%20breast%20tumours&amp;volume=406&amp;publication_year=2000&amp;pages=747-752&amp;pmid=10963602&amp;doi=10.1038/35021093&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib120">
<span class="label">120.</span><cite>Bagaev A, Kotlov N, Nomie K, et al. 
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell
2021. 
39
845–865.e7. ( 10.1016/j.ccell.2021.04.014)
</cite> [<a href="https://doi.org/10.1016/j.ccell.2021.04.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34019806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Conserved%20pan-cancer%20microenvironment%20subtypes%20predict%20response%20to%20immunotherapy&amp;volume=39&amp;publication_year=2021&amp;pages=845-865.e7&amp;pmid=34019806&amp;doi=10.1016/j.ccell.2021.04.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib121">
<span class="label">121.</span><cite>Hsieh W-C, Budiarto BR, Wang Y-F, et al. 
Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci
2022. 
29
96. ( 10.1186/s12929-022-00879-y)
</cite> [<a href="https://doi.org/10.1186/s12929-022-00879-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9661775/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36376874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biomed%20Sci&amp;title=Spatial%20multi-omics%20analyses%20of%20the%20tumor%20immune%20microenvironment&amp;volume=29&amp;publication_year=2022&amp;pages=96&amp;pmid=36376874&amp;doi=10.1186/s12929-022-00879-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib122">
<span class="label">122.</span><cite>Quek C, Pratapa A, Bai X, et al. 
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep
2024. 
43
114392. ( 10.1016/j.celrep.2024.114392)
</cite> [<a href="https://doi.org/10.1016/j.celrep.2024.114392" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38944836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=Single-cell%20spatial%20multiomics%20reveals%20tumor%20microenvironment%20vulnerabilities%20in%20cancer%20resistance%20to%20immunotherapy&amp;volume=43&amp;publication_year=2024&amp;pages=114392&amp;pmid=38944836&amp;doi=10.1016/j.celrep.2024.114392&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib123">
<span class="label">123.</span><cite>Larroquette M, Guegan J-P, Besse B, et al. 
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. J Immunother Cancer
2022. 
10
e003890. ( 10.1136/jitc-2021-003890)
</cite> [<a href="https://doi.org/10.1136/jitc-2021-003890" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9125754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35618288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Spatial%20transcriptomics%20of%20macrophage%20infiltration%20in%20non-small%20cell%20lung%20cancer%20reveals%20determinants%20of%20sensitivity%20and%20resistance%20to%20anti-PD1/PD-L1%20antibodies&amp;volume=10&amp;publication_year=2022&amp;pages=e003890&amp;pmid=35618288&amp;doi=10.1136/jitc-2021-003890&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib124">
<span class="label">124.</span><cite>Kovács SA, Fekete JT &amp; Győrffy B. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacol Sin
2023. 
44
1879–1889. ( 10.1038/s41401-023-01079-6)
</cite> [<a href="https://doi.org/10.1038/s41401-023-01079-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10462766/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37055532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmacol%20Sin&amp;title=Predictive%20biomarkers%20of%20immunotherapy%20response%20with%20pharmacological%20applications%20in%20solid%20tumors&amp;volume=44&amp;publication_year=2023&amp;pages=1879-1889&amp;pmid=37055532&amp;doi=10.1038/s41401-023-01079-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib125">
<span class="label">125.</span><cite>Chan TA, Yarchoan M, Jaffee E, et al. 
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol
2019. 
30
44–56. ( 10.1093/annonc/mdy495)
</cite> [<a href="https://doi.org/10.1093/annonc/mdy495" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6336005/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30395155/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Development%20of%20tumor%20mutation%20burden%20as%20an%20immunotherapy%20biomarker:%20utility%20for%20the%20oncology%20clinic&amp;volume=30&amp;publication_year=2019&amp;pages=44-56&amp;pmid=30395155&amp;doi=10.1093/annonc/mdy495&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib126">
<span class="label">126.</span><cite>Liu T, Han C, Wang S, et al. 
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol
2019. 
12
86. ( 10.1186/s13045-019-0770-1)
</cite> [<a href="https://doi.org/10.1186/s13045-019-0770-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6714445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Cancer-associated%20fibroblasts:%20an%20emerging%20target%20of%20anti-cancer%20immunotherapy&amp;volume=12&amp;publication_year=2019&amp;pages=86&amp;pmid=31462327&amp;doi=10.1186/s13045-019-0770-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib127">
<span class="label">127.</span><cite>Mongeon B, Hébert-Doutreloux J, Surendran A, et al. 
Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies. NPJ Syst Biol Appl
2024. 
10
91. ( 10.1038/s41540-024-00419-4)
</cite> [<a href="https://doi.org/10.1038/s41540-024-00419-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11330976/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39155294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Syst%20Biol%20Appl&amp;title=Spatial%20computational%20modelling%20illuminates%20the%20role%20of%20the%20tumour%20microenvironment%20for%20treating%20glioblastoma%20with%20immunotherapies&amp;volume=10&amp;publication_year=2024&amp;pages=91&amp;pmid=39155294&amp;doi=10.1038/s41540-024-00419-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib128">
<span class="label">128.</span><cite>Gong C, Milberg O, Wang B, et al. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. J R Soc Interface
2017. 
14
20170320. ( 10.1098/rsif.2017.0320)
</cite> [<a href="https://doi.org/10.1098/rsif.2017.0320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5636269/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28931635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20R%20Soc%20Interface&amp;title=A%20computational%20multiscale%20agent-based%20model%20for%20simulating%20spatio-temporal%20tumour%20immune%20response%20to%20PD1%20and%20PDL1%20inhibition&amp;volume=14&amp;publication_year=2017&amp;pages=20170320&amp;pmid=28931635&amp;doi=10.1098/rsif.2017.0320&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib129">
<span class="label">129.</span><cite>Ruiz-Martinez A, Gong C, Wang H, et al. 
Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. PLoS Comput Biol
2022. 
18
e1010254. ( 10.1371/journal.pcbi.1010254)
</cite> [<a href="https://doi.org/10.1371/journal.pcbi.1010254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9348712/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35867773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Comput%20Biol&amp;title=Simulations%20of%20tumor%20growth%20and%20response%20to%20immunotherapy%20by%20coupling%20a%20spatial%20agent-based%20model%20with%20a%20whole-patient%20quantitative%20systems%20pharmacology%20model&amp;volume=18&amp;publication_year=2022&amp;pages=e1010254&amp;pmid=35867773&amp;doi=10.1371/journal.pcbi.1010254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib130">
<span class="label">130.</span><cite>Metzcar J, Wang Y, Heiland R, et al. 
A review of cell-based computational modeling in cancer biology. JCO Clin Cancer Inform
2019. 
3
1–13. ( 10.1200/cci.18.00069)</cite> [<a href="https://doi.org/10.1200/cci.18.00069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6584763/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30715927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Clin%20Cancer%20Inform&amp;title=A%20review%20of%20cell-based%20computational%20modeling%20in%20cancer%20biology&amp;volume=3&amp;publication_year=2019&amp;pages=1-13&amp;pmid=30715927&amp;doi=10.1200/cci.18.00069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib131">
<span class="label">131.</span><cite>Prasasya RD, Tian D &amp; Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies. Semin Cancer Biol
2011. 
21
200–206. ( 10.1016/j.semcancer.2011.04.001)
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2011.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21511035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Semin%20Cancer%20Biol&amp;title=Analysis%20of%20cancer%20signaling%20networks%20by%20systems%20biology%20to%20develop%20therapies&amp;volume=21&amp;publication_year=2011&amp;pages=200-206&amp;pmid=21511035&amp;doi=10.1016/j.semcancer.2011.04.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Endocrine-Related Cancer are provided here courtesy of <strong>Bioscientifica Ltd.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1530/ERC-25-0067"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ERC-25-0067.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (657.9 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12372069/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12372069/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12372069%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372069/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12372069/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12372069/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40840524/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12372069/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40840524/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12372069/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12372069/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="mOf51hMNXjKiSvUOLntC5SkYnKOCYsW6CoIdeE0jqgrmPCaHixv2w6sdJRY8d1Vm">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
